1
|
Du H, Liu J, Jude KM, Yang X, Li Y, Bell B, Yang H, Kassardjian A, Mobedi A, Parekh U, Sperberg RAP, Julien JP, Mellins ED, Garcia KC, Huang PS. A general platform for targeting MHC-II antigens via a single loop. bioRxiv 2024:2024.01.26.577489. [PMID: 38352315 PMCID: PMC10862749 DOI: 10.1101/2024.01.26.577489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/21/2024]
Abstract
Class-II major histocompatibility complexes (MHC-IIs) are central to the communications between CD4+ T cells and antigen presenting cells (APCs), but intrinsic structural features associated with MHC-II make it difficult to develop a general targeting system with high affinity and antigen specificity. Here, we introduce a protein platform, Targeted Recognition of Antigen-MHC Complex Reporter for MHC-II (TRACeR-II), to enable the rapid development of peptide-specific MHC-II binders. TRACeR-II has a small helical bundle scaffold and uses an unconventional mechanism to recognize antigens via a single loop. This unique antigen-recognition mechanism renders this platform highly versatile and amenable to direct structural modeling of the interactions with the antigen. We demonstrate that TRACeR-II binders can be rapidly evolved across multiple alleles, while computational protein design can produce specific binding sequences for a SARS-CoV-2 peptide of unknown complex structure. TRACeR-II sheds light on a simple and straightforward approach to address the MHC peptide targeting challenge, without relying on combinatorial selection on complementarity determining region (CDR) loops. It presents a promising basis for further exploration in immune response modulation as well as a broad range of theragnostic applications.
Collapse
Affiliation(s)
- Haotian Du
- Department of Chemistry, Stanford University, Stanford, CA, USA
| | - Jingjia Liu
- Department of Bioengineering, Stanford University, CA, USA
| | - Kevin M. Jude
- Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Xinbo Yang
- Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Ying Li
- Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, USA
- Stanford Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA
| | - Braxton Bell
- Department of Chemistry, Stanford University, Stanford, CA, USA
| | - Hongli Yang
- Department of Bioengineering, Stanford University, CA, USA
| | - Audrey Kassardjian
- Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Ali Mobedi
- Department of Bioengineering, Stanford University, CA, USA
| | - Udit Parekh
- Department of Bioengineering, Stanford University, CA, USA
| | | | - Jean-Philippe Julien
- Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
- Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Elizabeth D. Mellins
- Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, USA
- Stanford Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA
| | - K. Christopher Garcia
- Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA
- Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA
| | - Po-Ssu Huang
- Department of Bioengineering, Stanford University, CA, USA
| |
Collapse
|
2
|
Khanna K, Yan H, Mehra M, Rohatgi N, Mbalaviele G, Mellins ED, Faccio R. Tmem178 Negatively Regulates IL-1β Production Through Inhibition of the NLRP3 Inflammasome. Arthritis Rheumatol 2024; 76:107-118. [PMID: 37534578 DOI: 10.1002/art.42666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2022] [Revised: 06/30/2023] [Accepted: 07/13/2023] [Indexed: 08/04/2023]
Abstract
OBJECTIVE Inflammasomes modulate the release of bioactive interleukin (IL)-1β. Excessive IL-1β levels are detected in patients with systemic juvenile idiopathic arthritis (sJIA) and cytokine storm syndrome (CSS) with mutated and unmutated inflammasome components, raising questions on the mechanisms of IL-1β regulation in these disorders. METHODS To investigate how the NLRP3 inflammasome is modulated in sJIA, we focused on Transmembrane protein 178 (Tmem178), a negative regulator of calcium levels in macrophages, and measured IL-1β and caspase-1 activation in wild-type (WT) and Tmem178-/- macrophages after calcium chelators, silencing of Stim1, a component of store-operated calcium entry (SOCE), or by expressing a Tmem178 mutant lacking the Stromal Interaction Molecule 1 (Stim1) binding site. Mitochondrial function in both genotypes was assessed by measuring oxidative respiration, mitochondrial reactive oxygen species (mtROS), and mitochondrial damage. CSS development was analyzed in Perforin-/- /Tmem178-/- mice infected with lymphocytic choriomeningitis virus (LCMV) in which inflammasome or IL-1β signaling was pharmacologically inhibited. Human TMEM178 and IL1B transcripts were analyzed in data sets of whole blood and peripheral blood monocytes from healthy controls and patients with active sJIA. RESULTS TMEM178 levels are reduced in whole blood and monocytes from patients with sJIA while IL1B levels are increased. Accordingly, Tmem178-/- macrophages produce elevated IL-1β compared with WT cells. The elevated intracellular calcium levels after SOCE activation in Tmem178-/- macrophages induce mitochondrial damage, release mtROS, and ultimately promote NLRP3 inflammasome activation. In vivo, inhibition of inflammasome or IL-1β neutralization prolongs Tmem178-/- mouse survival in LCMV-induced CSS. CONCLUSION Down-regulation of TMEM178 levels may represent a marker of disease activity and help identify patients who could benefit from inflammasome targeting.
Collapse
Affiliation(s)
- Kunjan Khanna
- Washington University in St. Louis, St. Louis, Missouri
| | - Hui Yan
- Washington University in St. Louis, St. Louis, Missouri
| | | | - Nidhi Rohatgi
- Washington University in St. Louis, St. Louis, Missouri
| | | | | | - Roberta Faccio
- Washington University in St. Louis and Shriners Hospital for Children, St. Louis, Missouri
| |
Collapse
|
3
|
Frankovich J, Nanda H, Mellins ED, Jyonouchi H, Boles RG, Walker SJ, Gaitanis J, Frye RE. Synchrony 2022: The Role of Neuroinflammation in Behavioral Exacerbations in Autism Spectrum Disorder. J Pers Med 2023; 13:1133. [PMID: 37511746 PMCID: PMC10381638 DOI: 10.3390/jpm13071133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Accepted: 07/05/2023] [Indexed: 07/30/2023] Open
Abstract
The BRAIN Foundation (Pleasanton, CA) hosted Synchrony 2022, a medical conference focusing on research for treatments to benefit individuals with neurodevelopmental disorders (NDD), including those with autism spectrum disorders (ASD) [...].
Collapse
Affiliation(s)
- Jennifer Frankovich
- Lucile Packard Children's Hospital, Stanford School of Medicine, Stanford, CA 94010, USA
| | - Heer Nanda
- University of California, Berkeley, CA 94720, USA
| | - Elizabeth D Mellins
- Lucile Packard Children's Hospital, Stanford School of Medicine, Stanford, CA 94010, USA
| | | | - Richard G Boles
- NeurAbilities, Vorhees, NJ 08043, USA
- NeuroNeeds®, Old Lyme, CT 06371, USA
| | - Stephen J Walker
- Wake Forest Institute for Regenerative Medicine, Winston Salem, NC 27101, USA
| | - John Gaitanis
- Hasbro Children's Hospital, Brown University, Providence, RI 02903, USA
| | - Richard E Frye
- Autism Discovery and Treatment Foundation, Phoenix, AZ 85050, USA
| |
Collapse
|
4
|
Kalinowski A, Tian L, Pattni R, Ollila H, Khan M, Manko C, Silverman M, Ma M, Columbo L, Farhadian B, Swedo S, Murphy T, Johnson M, Fernell E, Gillberg C, Thienemann M, Mellins ED, Levinson DF, Urban AE, Frankovich J. Evaluation of C4 Gene Copy Number in Pediatric Acute Neuropsychiatric Syndrome. Dev Neurosci 2023; 45:315-324. [PMID: 37379808 DOI: 10.1159/000531707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 06/16/2023] [Indexed: 06/30/2023] Open
Abstract
Pediatric acute-onset neuropsychiatric syndrome (PANS) is an abrupt-onset neuropsychiatric disorder. PANS patients have an increased prevalence of comorbid autoimmune illness, most commonly arthritis. In addition, an estimated one-third of PANS patients present with low serum C4 protein, suggesting decreased production or increased consumption of C4 protein. To test the possibility that copy number (CN) variation contributes to risk of PANS illness, we compared mean total C4A and total C4B CN in ethnically matched subjects from PANS DNA samples and controls (192 cases and 182 controls). Longitudinal data from the Stanford PANS cohort (n = 121) were used to assess whether the time to juvenile idiopathic arthritis (JIA) or autoimmune disease (AI) onset was a function of total C4A or C4B CN. Lastly, we performed several hypothesis-generating analyses to explore the correlation between individual C4 gene variants, sex, specific genotypes, and age of PANS onset. Although the mean total C4A or C4B CN did not differ in PANS compared to controls, PANS patients with low C4B CN were at increased risk for subsequent JIA diagnosis (hazard ratio = 2.7, p value = 0.004). We also observed a possible increase in risk for AI in PANS patients and a possible correlation between lower C4B and PANS age of onset. An association between rheumatoid arthritis and low C4B CN has been reported previously. However, patients with PANS develop different types of JIA: enthesitis-related arthritis, spondyloarthritis, and psoriatic arthritis. This suggests that C4B plays a role that spans these arthritis types.
Collapse
Affiliation(s)
- Agnieszka Kalinowski
- Stanford University Department of Psychiatry and Behavioral Sciences, Stanford, California, USA
- Sierra Pacific Mental Illness Research Education and Clinical Center (MIRECC), VA Palo Alto Health Care System, Palo Alto, California, USA
| | - Lu Tian
- Stanford University Department of Biomedical Data Science, Stanford, California, USA
| | - Reenal Pattni
- Stanford University Department of Psychiatry and Behavioral Sciences, Stanford, California, USA
- Stanford University Department of Genetics, Stanford, California, USA
| | - Hanna Ollila
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA
- Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
- Broad Institute of MIT and Harvard, Boston, Massachusetts, USA
| | - Maroof Khan
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| | - Cindy Manko
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| | - Melissa Silverman
- Stanford University Department of Psychiatry and Behavioral Sciences, Stanford, California, USA
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| | - Meiqian Ma
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| | - Laurie Columbo
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| | - Bahare Farhadian
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| | - Susan Swedo
- National Institutes of Health, Pediatrics and Developmental Neuroscience Branch, Bethesda, Maryland, USA
| | - Tanya Murphy
- Department of Pediatrics and Department of Psychiatry and Neurosciences, University of South Florida, Tampa, Florida, USA
- John Hopkins Medicine, Baltimore, Maryland, USA
| | - Mats Johnson
- Gillberg Neuropsychiatry Centre, University of Gothenburg, Gothenburg, Sweden
| | - Elisabeth Fernell
- Gillberg Neuropsychiatry Centre, University of Gothenburg, Gothenburg, Sweden
| | | | - Margo Thienemann
- Stanford University Department of Psychiatry and Behavioral Sciences, Stanford, California, USA
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| | - Elizabeth D Mellins
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| | - Douglas F Levinson
- Stanford University Department of Psychiatry and Behavioral Sciences, Stanford, California, USA
| | - Alexander E Urban
- Stanford University Department of Psychiatry and Behavioral Sciences, Stanford, California, USA
- Stanford University Department of Genetics, Stanford, California, USA
| | - Jennifer Frankovich
- Immune Behavioral Health Clinic, Stanford University Department of Pediatrics, Stanford, California, USA
| |
Collapse
|
5
|
Movassagh H, Prunicki M, Kaushik A, Zhou X, Dunham D, Smith EM, He Z, Aleman Muench GR, Shi M, Weimer AK, Cao S, Andorf S, Feizi A, Snyder MP, Soroosh P, Mellins ED, Nadeau KC. Proinflammatory polarization of monocytes by particulate air pollutants is mediated by induction of trained immunity in pediatric asthma. Allergy 2023. [PMID: 36929161 DOI: 10.1111/all.15692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 01/10/2023] [Accepted: 01/24/2023] [Indexed: 03/18/2023]
Abstract
BACKGROUND The impact of exposure to air pollutants, such as fine particulate matter (PM), on the immune system and its consequences on pediatric asthma, are not well understood. We investigated whether ambient levels of fine PM with aerodynamic diameter ≤2.5 microns (PM2.5 ) are associated with alterations in circulating monocytes in children with or without asthma. METHODS Monocyte phenotyping was performed by cytometry time-of-flight (CyTOF). Cytokines were measured using cytometric bead array and Luminex assay. ChIP-Seq was utilized to address histone modifications in monocytes. RESULTS Increased exposure to ambient PM2.5 was linked to specific monocyte subtypes, particularly in children with asthma. Mechanistically, we hypothesized that innate trained immunity is evoked by a primary exposure to fine PM and accounts for an enhanced inflammatory response after secondary stimulation in vitro. We determined that the trained immunity was induced in circulating monocytes by fine particulate pollutants, and it was characterized by the upregulation of proinflammatory mediators, such as TNF, IL-6, and IL-8, upon stimulation with house dust mite or lipopolysaccharide. This phenotype was epigenetically controlled by enhanced H3K27ac marks in circulating monocytes. CONCLUSION The specific alterations of monocytes after ambient pollution exposure suggest a possible prognostic immune signature for pediatric asthma, and pollution-induced trained immunity may provide a potential therapeutic target for asthmatic children living in areas with increased air pollution.
Collapse
Affiliation(s)
- Hesam Movassagh
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| | - Mary Prunicki
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| | - Abhinav Kaushik
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| | - Xiaoying Zhou
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| | - Diane Dunham
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| | - Eric M Smith
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| | - Ziyuan He
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| | | | - Minyi Shi
- Department of Genetics, Stanford University School of Medicine, Stanford, California, USA
- Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Annika K Weimer
- Department of Genetics, Stanford University School of Medicine, Stanford, California, USA
- Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Shu Cao
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| | - Sandra Andorf
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
- Divisions of Biomedical Informatics and Allergy & Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | | | - Michael P Snyder
- Department of Genetics, Stanford University School of Medicine, Stanford, California, USA
- Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Pejman Soroosh
- Janssen Research & Development, LLC, San Diego, California, USA
| | - Elizabeth D Mellins
- Department of Pediatrics, Stanford Program in Immunology, Stanford University School of Medicine, Stanford, California, USA
| | - Kari C Nadeau
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA
| |
Collapse
|
6
|
Huang Z, You X, Chen L, Du Y, Brodeur K, Jee H, Wang Q, Linder G, Darbousset R, Cunin P, Chang MH, Wactor A, Wauford BM, Todd MJC, Wei K, Li Y, Levescot A, Iwakura Y, Pascual V, Baldwin NE, Quartier P, Li T, Gianatasio MT, Hasserjian RP, Henderson LA, Sykes DB, Mellins ED, Canna SW, Charles JF, Nigrovic PA, Lee PY. mTORC1 links pathology in experimental models of Still's disease and macrophage activation syndrome. Nat Commun 2022; 13:6915. [PMID: 36443301 PMCID: PMC9705324 DOI: 10.1038/s41467-022-34480-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 10/26/2022] [Indexed: 11/29/2022] Open
Abstract
Still's disease is a severe inflammatory syndrome characterized by fever, skin rash and arthritis affecting children and adults. Patients with Still's disease may also develop macrophage activation syndrome, a potentially fatal complication of immune dysregulation resulting in cytokine storm. Here we show that mTORC1 (mechanistic target of rapamycin complex 1) underpins the pathology of Still's disease and macrophage activation syndrome. Single-cell RNA sequencing in a murine model of Still's disease shows preferential activation of mTORC1 in monocytes; both mTOR inhibition and monocyte depletion attenuate disease severity. Transcriptomic data from patients with Still's disease suggest decreased expression of the mTORC1 inhibitors TSC1/TSC2 and an mTORC1 gene signature that strongly correlates with disease activity and treatment response. Unrestricted activation of mTORC1 by Tsc2 deletion in mice is sufficient to trigger a Still's disease-like syndrome, including both inflammatory arthritis and macrophage activation syndrome with hemophagocytosis, a cellular manifestation that is reproduced in human monocytes by CRISPR/Cas-mediated deletion of TSC2. Consistent with this observation, hemophagocytic histiocytes from patients with macrophage activation syndrome display prominent mTORC1 activity. Our study suggests a mechanistic link of mTORC1 to inflammation that connects the pathogenesis of Still's disease and macrophage activation syndrome.
Collapse
Affiliation(s)
- Zhengping Huang
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA ,grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA ,grid.413405.70000 0004 1808 0686Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China
| | - Xiaomeng You
- grid.38142.3c000000041936754XDepartment of Orthopaedic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Liang Chen
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Yan Du
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA ,grid.412465.0Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
| | - Kailey Brodeur
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Hyuk Jee
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Qiang Wang
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Grace Linder
- grid.239552.a0000 0001 0680 8770Blood Bank and Transfusion Medicine Division, Children’s Hospital of Philadelphia, Philadelphia, PA USA
| | - Roxane Darbousset
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Pierre Cunin
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Margaret H. Chang
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Alexandra Wactor
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Brian M. Wauford
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Marc J. C. Todd
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Kevin Wei
- grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Ying Li
- grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Anais Levescot
- grid.462336.6Université Paris Cité, Institut Imagine, INSERM UMR1163, Laboratory Intestinal Immunity, Paris, France
| | - Yoichiro Iwakura
- grid.143643.70000 0001 0660 6861Centre for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan
| | - Virginia Pascual
- grid.5386.8000000041936877XDepartment of Pediatrics and Drukier Institute for Children’s Health, Weill Cornell Medicine, New York, NY USA
| | - Nicole E. Baldwin
- grid.486749.00000 0004 4685 2620Baylor Scott & White Research Institute, Dallas, TX USA
| | - Pierre Quartier
- grid.5842.b0000 0001 2171 2558Pediatric Immunology, Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Assistance Publique-Hopitaux de Paris, Universite de Paris, Paris, France
| | - Tianwang Li
- grid.413405.70000 0004 1808 0686Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China
| | - Maria T. Gianatasio
- grid.416636.00000 0004 0460 4960Mass General Brigham Healthcare Center - Salem Hospital, Salem, MA USA
| | - Robert P. Hasserjian
- grid.38142.3c000000041936754XDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
| | - Lauren A. Henderson
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - David B. Sykes
- grid.32224.350000 0004 0386 9924Center for Regenerative Medicine, Massachusetts General Hospital, Boston, USA
| | - Elizabeth D. Mellins
- grid.168010.e0000000419368956Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA USA
| | - Scott W. Canna
- grid.239552.a0000 0001 0680 8770Division of Rheumatology, Children’s Hospital of Philadelphia, Philadelphia, PA USA
| | - Julia F. Charles
- grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA ,grid.38142.3c000000041936754XDepartment of Orthopaedic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Peter A. Nigrovic
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA ,grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Pui Y. Lee
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| |
Collapse
|
7
|
Li Y, Jiang W, Mellins ED. TCR-like antibodies targeting autoantigen-mhc complexes: a mini-review. Front Immunol 2022; 13:968432. [PMID: 35967436 PMCID: PMC9363607 DOI: 10.3389/fimmu.2022.968432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 07/06/2022] [Indexed: 11/13/2022] Open
Abstract
T cell receptors (TCRs) recognize peptide antigens bound to major histocompatibility complex (MHC) molecules (p/MHC) that are expressed on cell surfaces; while B cell-derived antibodies (Abs) recognize soluble or cell surface native antigens of various types (proteins, carbohydrates, etc.). Immune surveillance by T and B cells thus inspects almost all formats of antigens to mount adaptive immune responses against cancer cells, infectious organisms and other foreign insults, while maintaining tolerance to self-tissues. With contributions from environmental triggers, the development of autoimmune disease is thought to be due to the expression of MHC risk alleles by antigen-presenting cells (APCs) presenting self-antigen (autoantigen), breaking through self-tolerance and activating autoreactive T cells, which orchestrate downstream pathologic events. Investigating and treating autoimmune diseases have been challenging, both because of the intrinsic complexity of these diseases and the need for tools targeting T cell epitopes (autoantigen-MHC). Naturally occurring TCRs with relatively low (micromolar) affinities to p/MHC are suboptimal for autoantigen-MHC targeting, whereas the use of engineered TCRs and their derivatives (e.g., TCR multimers and TCR-engineered T cells) are limited by unpredictable cross-reactivity. As Abs generally have nanomolar affinity, recent advances in engineering TCR-like (TCRL) Abs promise advantages over their TCR counterparts for autoantigen-MHC targeting. Here, we compare the p/MHC binding by TCRs and TCRL Abs, review the strategies for generation of TCRL Abs, highlight their application for identification of autoantigen-presenting APCs, and discuss future directions and limitations of TCRL Abs as immunotherapy for autoimmune diseases.
Collapse
Affiliation(s)
- Ying Li
- Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, United States
- Stanford Program in Immunology, Stanford University School of Medicine, Stanford, CA, United States
| | - Wei Jiang
- Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, United States
- Stanford Program in Immunology, Stanford University School of Medicine, Stanford, CA, United States
- *Correspondence: Wei Jiang, ; Elizabeth D. Mellins,
| | - Elizabeth D. Mellins
- Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, United States
- Stanford Program in Immunology, Stanford University School of Medicine, Stanford, CA, United States
- *Correspondence: Wei Jiang, ; Elizabeth D. Mellins,
| |
Collapse
|
8
|
Chakraborty S, Gonzalez JC, Sievers BL, Mallajosyula V, Chakraborty S, Dubey M, Ashraf U, Cheng BYL, Kathale N, Tran KQT, Scallan C, Sinnott A, Cassidy A, Chen ST, Gelbart T, Gao F, Golan Y, Ji X, Kim-Schulze S, Prahl M, Gaw SL, Gnjatic S, Marron TU, Merad M, Arunachalam PS, Boyd SD, Davis MM, Holubar M, Khosla C, Maecker HT, Maldonado Y, Mellins ED, Nadeau KC, Pulendran B, Singh U, Subramanian A, Utz PJ, Sherwood R, Zhang S, Jagannathan P, Tan GS, Wang TT. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Sci Transl Med 2022; 14:eabm7853. [PMID: 35040666 PMCID: PMC8939764 DOI: 10.1126/scitranslmed.abm7853] [Citation(s) in RCA: 61] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Accepted: 01/07/2022] [Indexed: 12/20/2022]
Abstract
A damaging inflammatory response is implicated in the pathogenesis of severe coronavirus disease 2019 (COVID-19), but mechanisms contributing to this response are unclear. In two prospective cohorts, early non-neutralizing, afucosylated immunoglobulin G (IgG) antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were associated with progression from mild to more severe COVID-19. To study the biology of afucosylated IgG immune complexes, we developed an in vivo model that revealed that human IgG-Fc-gamma receptor (FcγR) interactions could regulate inflammation in the lung. Afucosylated IgG immune complexes isolated from patients with COVID-19 induced inflammatory cytokine production and robust infiltration of the lung by immune cells. In contrast to the antibody structures that were associated with disease progression, antibodies that were elicited by messenger RNA SARS-CoV-2 vaccines were highly fucosylated and enriched in sialylation, both modifications that reduce the inflammatory potential of IgG. Vaccine-elicited IgG did not promote an inflammatory lung response. These results show that human IgG-FcγR interactions regulate inflammation in the lung and define distinct lung activities mediated by the IgG that are associated with protection against, or progression to, severe COVID-19.
Collapse
Affiliation(s)
- Saborni Chakraborty
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
| | - Joseph C. Gonzalez
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
- Program in Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | | | - Vamsee Mallajosyula
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Srijoni Chakraborty
- Department of Computer and Software Engineering, San Jose State University, San Jose, CA, 95192, USA
| | - Megha Dubey
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Usama Ashraf
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
| | - Bowie Yik-Ling Cheng
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
| | - Nimish Kathale
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
| | - Kim Quyen Thi Tran
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
| | - Courtney Scallan
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
| | | | - Arianna Cassidy
- Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, 94143, USA
| | - Steven T. Chen
- The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
| | | | - Fei Gao
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Yarden Golan
- Department of Bioengineering and Therapeutic Sciences, and Institute for Human Genetics, University of California San Francisco, San Francisco, CA, 94143, USA
| | - Xuhuai Ji
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Seunghee Kim-Schulze
- The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
| | - Mary Prahl
- Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, CA, 94143, USA
| | - Stephanie L. Gaw
- Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, 94143, USA
| | - Sacha Gnjatic
- The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- Human Immune Monitoring Center, Precision Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
| | - Thomas U. Marron
- The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
| | - Miriam Merad
- The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
- Human Immune Monitoring Center, Precision Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-5674, USA
| | - Prabhu S. Arunachalam
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Scott D. Boyd
- Departments of Pathology and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Mark M. Davis
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Marisa Holubar
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
| | - Chaitan Khosla
- Departments of Chemistry and Chemical Engineering, Stanford University, Stanford, CA, 94305, USA
| | - Holden T. Maecker
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Yvonne Maldonado
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Elizabeth D. Mellins
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Kari C. Nadeau
- Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA, 94304, USA
| | - Bali Pulendran
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Upinder Singh
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Aruna Subramanian
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
| | - Paul J. Utz
- Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 94304, USA
| | - Robert Sherwood
- Proteomics and Metabolomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY, 14853, USA
| | - Sheng Zhang
- Proteomics and Metabolomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY, 14853, USA
| | - Prasanna Jagannathan
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Gene S. Tan
- J. Craig Venter Institute, La Jolla, CA, 92037, USA
- Division of Infectious Diseases, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA
| | - Taia T. Wang
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, 94304, USA
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Chan Zuckerberg Biohub, San Francisco, CA, 94158, USA
| |
Collapse
|
9
|
Saper VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, Prahalad S, Canna S, Shimizu C, Deutsch G, Tan SY, Remmers EF, Monos D, Hahn T, Phadke OK, Cassidy E, Ferguson I, Mallajosyula V, Xu J, Rosa Duque JS, Chua GT, Ghosh D, Szymanski AM, Rubin D, Burns JC, Tian L, Fernandez-Vina MA, Mellins ED, Hollenbach JA. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis 2022; 81:406-415. [PMID: 34789453 PMCID: PMC10564446 DOI: 10.1136/annrheumdis-2021-220578] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 09/29/2021] [Indexed: 12/11/2022]
Abstract
OBJECTIVES Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, delayed hypersensitivity reaction (DHR). We observed DRESS to inhibitors of interleukin 1 (IL-1) or IL-6 in a small group of patients with Still's disease with atypical lung disease. We sought to characterise features of patients with Still's disease with DRESS compared with drug-tolerant Still's controls. We analysed human leucocyte antigen (HLA) alleles for association to inhibitor-related DHR, including in a small Kawasaki disease (KD) cohort. METHODS In a case/control study, we collected a multicentre series of patients with Still's disease with features of inhibitor-related DRESS (n=66) and drug-tolerant Still's controls (n=65). We retrospectively analysed clinical data from all Still's subjects and typed 94/131 for HLA. European Still's-DRESS cases were ancestry matched to International Childhood Arthritis Genetics Consortium paediatric Still's cases (n=550) and compared for HLA allele frequencies. HLA association also was analysed using Still's-DRESS cases (n=64) compared with drug-tolerant Still's controls (n=30). KD subjects (n=19) were similarly studied. RESULTS Still's-DRESS features included eosinophilia (89%), AST-ALT elevation (75%) and non-evanescent rash (95%; 88% involving face). Macrophage activation syndrome during treatment was frequent in Still's-DRESS (64%) versus drug-tolerant Still's (3%; p=1.2×10-14). We found striking enrichment for HLA-DRB1*15 haplotypes in Still's-DRESS cases versus INCHARGE Still's controls (p=7.5×10-13) and versus self-identified, ancestry-matched Still's controls (p=6.3×10-10). In the KD cohort, DRB1*15:01 was present only in those with suspected anakinra reactions. CONCLUSIONS DRESS-type reactions occur among patients treated with IL-1/IL-6 inhibitors and strongly associate with common HLA-DRB1*15 haplotypes. Consideration of preprescription HLA typing and vigilance for serious reactions to these drugs are warranted.
Collapse
Affiliation(s)
- Vivian E Saper
- Pediatrics, Stanford University, Stanford, California, USA
| | - Michael J Ombrello
- Translational Genetics and Genomics Unit, NIAMS, National Institutes of Health, Bethesda, Maryland, USA
| | | | - Gonzalo Montero-Martin
- Stanford Blood Center, Histocompatibility and Immunogenetics Laboratory, Stanford University, Stanford, California, USA
| | - Sampath Prahalad
- Children's Healthcare of Atlanta, Atlanta, Georgia, USA
- Pediatrics, Emory University, Atlanta, Georgia, USA
| | - Scott Canna
- Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Chisato Shimizu
- Pediatrics, University of California San Diego, La Jolla, California, USA
| | - Gail Deutsch
- Pathology, Seattle Children's Hospital, Seattle, Washington, USA
| | - Serena Y Tan
- Pathology, Stanford University, Stanford, California, USA
| | - Elaine F Remmers
- National Human Genome Research Institute, Bethesda, Maryland, USA
| | - Dimitri Monos
- Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Timothy Hahn
- Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
| | | | - Elaine Cassidy
- Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Ian Ferguson
- Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA
| | | | - Jianpeng Xu
- Pediatrics, Stanford University, Stanford, California, USA
| | - Jaime S Rosa Duque
- Pediatrics, University of Hong Kong, Hong Kong Special Adminstrative District, China
| | - Gilbert T Chua
- Pediatrics, University of Hong Kong, Hong Kong Special Adminstrative District, China
| | - Debopam Ghosh
- Pediatrics, Stanford University, Stanford, California, USA
| | - Ann Marie Szymanski
- Translational Genetics and Genomics Unit, NIAMS, National Institutes of Health, Bethesda, Maryland, USA
| | - Danielle Rubin
- Translational Genetics and Genomics Unit, NIAMS, National Institutes of Health, Bethesda, Maryland, USA
| | - Jane C Burns
- Pediatrics, University of California San Diego, La Jolla, California, USA
| | - Lu Tian
- Biomedical Data Science, Stanford University, Stanford, California, USA
| | - Marcelo A Fernandez-Vina
- Stanford Blood Center, Histocompatibility and Immunogenetics Laboratory, Stanford University, Stanford, California, USA
| | | | - Jill A Hollenbach
- Neurology, University of California San Francisco, San Francisco, California, USA
| |
Collapse
|
10
|
Macaubas C, Rahman SS, Lavi I, Haddad A, Elias M, Sengupta D, Zisman D, Mellins ED. High Dimensional Analyses of Circulating Immune Cells in Psoriatic Arthritis Detects Elevated Phosphorylated STAT3. Front Immunol 2022; 12:758418. [PMID: 35087513 PMCID: PMC8787828 DOI: 10.3389/fimmu.2021.758418] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 12/20/2021] [Indexed: 01/31/2023] Open
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis, affecting up to 40% of patients with psoriasis. Constitutive expression by CD4+ T cells of an active form of STAT3, a signal transducer and transcription factor, has been shown to induce many of the major features of PsA in an animal model. We used high dimensional mass cytometry (CyTOF) to probe ex-vivo levels of phosphorylated STAT3 (pSTAT3) in circulating immune cell subpopulations from PsA patients during active and inactive states. We evaluated the frequency of 16 immune cell populations and the levels of the activated forms of STAT3 (pSTAT3) and, for comparison, STAT1 (pSTAT1) and Src (pSrc) in whole blood fixed shortly after collection. In addition to PsA patients, we studied active rheumatoid arthritis (RA) patients. Increased levels of pSTAT3 were found in all the CD4+ T cell subsets analyzed, specifically, Th1, Th2, Th17, T follicular helper (Tfh) and T regulatory (Treg) as well as in CD14+CD16- (classical) monocytes from active PsA patients compared to inactive patients. After correcting for body mass index (BMI), smoking and conventional disease modifying antirheumatic drugs (c-DMARDs), levels of pSTAT3 levels remained increased in Th1 and Tfh CD4+ T cells, and in CD14+CD16- monocytes from active patients compared to inactive patients. No differences between the patient groups were observed for pSTAT1 or pSrc. No differences were found between the active PsA and active RA groups after correction for multiple testing. During active PsA, circulating Th1 and Tfh CD4+ T cells, and CD14+CD16- monocytes expressing high levels of pSTAT3 may play a role in PsA pathophysiology, perhaps by migration to inflamed sites.
Collapse
Affiliation(s)
- Claudia Macaubas
- Pediatrics, Program in Immunology, Stanford University, Stanford, CA, United States
| | - Shamma S Rahman
- Pediatrics, Program in Immunology, Stanford University, Stanford, CA, United States
| | - Idit Lavi
- Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel
| | - Amir Haddad
- Rheumatology Unit, Carmel Medical Center, Haifa, Israel
| | - Muna Elias
- Rheumatology Unit, Carmel Medical Center, Haifa, Israel
| | | | - Devy Zisman
- Rheumatology Unit, Carmel Medical Center, Haifa, Israel.,The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Elizabeth D Mellins
- Pediatrics, Program in Immunology, Stanford University, Stanford, CA, United States
| |
Collapse
|
11
|
Chen G, Deutsch GH, Schulert G, Zheng H, Jang S, Trapnell B, Lee P, Macaubas C, Ho K, Schneider C, Saper VE, de Jesus AA, Krasnow M, Grom A, Goldbach-Mansky R, Khatri P, Mellins ED, Canna SW. Serum proteome analysis of systemic JIA and related lung disease identifies distinct inflammatory programs and biomarkers. Arthritis Rheumatol 2022; 74:1271-1283. [PMID: 35189047 DOI: 10.1002/art.42099] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 01/16/2022] [Accepted: 02/15/2022] [Indexed: 11/08/2022]
Abstract
OBJECTIVES Recent observations in systemic Juvenile Idiopathic Arthritis (sJIA) suggest an increasing incidence of high-mortality interstitial lung disease (sJIA-LD) often characterized by a variant of pulmonary alveolar proteinosis (PAP). Co-occurrence of macrophage activation syndrome (MAS) and PAP in sJIA suggested a shared pathology, but sJIA-LD patients also commonly experience features of drug reaction such as atypical rashes and eosinophilia. We sought to investigate immunopathology and identify biomarkers in sJIA, MAS, and sJIA-LD. METHODS We used SOMAscan to measure >1300 analytes in sera from healthy controls and patients with sJIA, MAS, sJIA-LD and other related diseases. We verified selected findings by ELISA and lung immunostaining. Because the proteome of a sample may reflect multiple states (sJIA, MAS, sJIA-LD), we used regression modeling to identify subsets of altered proteins associated with each state. We tested key findings in a validation cohort. RESULTS Proteome alterations in active sJIA and MAS overlapped substantially, including known sJIA biomarkers like SAA and S100A9, and novel elevations of heat shock proteins and glycolytic enzymes. IL-18 was elevated in all sJIA groups, particularly MAS and sJIA-LD. We also identified an MAS-independent sJIA-LD signature notable for elevated ICAM5, MMP7, and allergic/eosinophilic chemokines, which have been previously associated with lung damage. Immunohistochemistry localized ICAM5 and MMP7 in sJIA-LD lung. ICAM5's ability to distinguish sJIA-LD from sJIA/MAS was independently validated. CONCLUSION Serum proteins support an sJIA-to-MAS continuum, help distinguish sJIA, sJIA/MAS, and sJIA-LD and suggest etiologic hypotheses. Select biomarkers, such as ICAM5, could aid in early detection and management of sJIA-LD.
Collapse
Affiliation(s)
- Guangbo Chen
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA
| | - Gail H Deutsch
- Pathology, Seattle Children's Hospital and University of Washington Medical Center, Seattle, WA, USA
| | - Grant Schulert
- Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Hong Zheng
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.,Center for Biomedical Informatics Research, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA
| | - SoRi Jang
- Biochemistry, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA
| | - Bruce Trapnell
- Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Pui Lee
- Pediatric Rheumatology, Boston Children's Hospital and Harvard School of Medicine, Boston, MA, USA
| | - Claudia Macaubas
- Pediatrics, Program in Immunology, School of Medicine, Stanford University, Stanford, CA, USA
| | - Katherine Ho
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.,Center for Biomedical Informatics Research, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA
| | - Corinne Schneider
- Pediatrics, UPMC Children's Hospital & University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Vivian E Saper
- Pediatrics, School of Medicine, Stanford University, Stanford, California, USA
| | - Adriana Almeida de Jesus
- Translational Autoinflammatory Disease Section, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Mark Krasnow
- Biochemistry, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA
| | - Alexei Grom
- Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Raphaela Goldbach-Mansky
- Translational Autoinflammatory Disease Section, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Purvesh Khatri
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.,Center for Biomedical Informatics Research, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA
| | - Elizabeth D Mellins
- Pediatrics, Program in Immunology, School of Medicine, Stanford University, Stanford, CA, USA
| | - Scott W Canna
- Pediatrics, UPMC Children's Hospital & University of Pittsburgh Medical Center, Pittsburgh, PA, USA.,Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| |
Collapse
|
12
|
Saper VE, Chen G, Khatri P, Mellins ED. Response to: ‘Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report’ by Bader-Meunier et al. Ann Rheum Dis 2022; 81:e21. [DOI: 10.1136/annrheumdis-2020-217000] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2020] [Accepted: 02/03/2020] [Indexed: 11/04/2022]
|
13
|
Abstract
Mapping MHC-II binding peptides derived from an antigenic protein for potential CD4+ T-cell epitopes has been challenging due to a lack of experimental approaches that are both quantitative and rapid. The rate-limiting steps in current approaches include the construction of single MHC allele expressing cell lines and/or the purification of the MHC-II allelic proteins for peptide elution (i.e., mass spectrometry) or in vitro peptide binding (i.e., ELISA) assays. These labor-intensive steps typically take up to 4 months or more. In this protocol, we describe a system that uses yeast cells to display "empty" (i.e., without covalently linked peptides) MHC-II heterodimers that are capable of binding exogenously added peptides of interest. This yeast-MHC-II system eliminates the time-consuming soluble MHC-II purification steps, allowing rapid identification of peptide ligands from protein antigens (RIPPA). The amount of peptide loading to MHC-II or the extent of competition between indicator and competitor peptides at the surface of yeast cells can be quantitatively determined using flow cytometric analysis. Importantly, the protocol only takes ∼1 month from the construction of plasmids and the yeast display of "empty" MHC-II to the quantitative determination of MHC-II binding peptides from a given antigen. © 2022 Wiley Periodicals LLC. Basic Protocol 1: Yeast display of "empty" MHC-II Support Protocol: Construction of yeast shuttle vector expressing "empty" MHC-II Basic Protocol 2: Peptide competition on the surface of yeast cells Alternate Protocol: RIPPA in a 96-well format.
Collapse
Affiliation(s)
- Rongzeng Liu
- Department of Pediatrics-Human Gene Therapy, Stanford University School of Medicine, Stanford, California.,Stanford Immunology, Stanford University School of Medicine, Stanford, California.,Department of Immunology, Henan University of Science and Technology School of Medicine, Luoyang, China
| | - Wei Jiang
- Department of Pediatrics-Human Gene Therapy, Stanford University School of Medicine, Stanford, California.,Stanford Immunology, Stanford University School of Medicine, Stanford, California
| | - Ying Li
- Department of Pediatrics-Human Gene Therapy, Stanford University School of Medicine, Stanford, California.,Stanford Immunology, Stanford University School of Medicine, Stanford, California
| | - Elizabeth D Mellins
- Department of Pediatrics-Human Gene Therapy, Stanford University School of Medicine, Stanford, California.,Stanford Immunology, Stanford University School of Medicine, Stanford, California
| |
Collapse
|
14
|
Olsson N, Jiang W, Adler LN, Mellins ED, Elias JE. Tuning DO:DM ratios modulates MHC class II immunopeptidomes. Mol Cell Proteomics 2022; 21:100204. [DOI: 10.1016/j.mcpro.2022.100204] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 01/07/2022] [Accepted: 01/16/2022] [Indexed: 10/19/2022] Open
|
15
|
Chakraborty S, Gonzalez JC, Sievers BL, Mallajosyula V, Chakraborty S, Dubey M, Ashraf U, Cheng BYL, Kathale N, Tran KQT, Scallan C, Sinnott A, Cassidy A, Chen ST, Gelbart T, Gao F, Golan Y, Ji X, Kim-Schulze S, Prahl M, Gaw SL, Gnjatic S, Marron TU, Merad M, Arunachalam PS, Boyd SD, Davis MM, Holubar M, Khosla C, Maecker HT, Maldonado Y, Mellins ED, Nadeau KC, Pulendran B, Singh U, Subramanian A, Utz PJ, Sherwood R, Zhang S, Jagannathan P, Tan GS, Wang TT. Structurally and functionally distinct early antibody responses predict COVID-19 disease trajectory and mRNA vaccine response. bioRxiv 2021:2021.05.25.445649. [PMID: 34075376 PMCID: PMC8168384 DOI: 10.1101/2021.05.25.445649] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A damaging inflammatory response is strongly implicated in the pathogenesis of severe COVID-19 but mechanisms contributing to this response are unclear. In two prospective cohorts, early non-neutralizing, afucosylated, anti-SARS-CoV-2 IgG predicted progression from mild, to more severe COVID-19. In contrast to the antibody structures that predicted disease progression, antibodies that were elicited by mRNA SARS-CoV-2 vaccines were low in Fc afucosylation and enriched in sialylation, both modifications that reduce the inflammatory potential of IgG. To study the biology afucosylated IgG immune complexes, we developed an in vivo model which revealed that human IgG-FcγR interactions can regulate inflammation in the lung. Afucosylated IgG immune complexes induced inflammatory cytokine production and robust infiltration of the lung by immune cells. By contrast, vaccine elicited IgG did not promote an inflammatory lung response. Here, we show that IgG-FcγR interactions can regulate inflammation in the lung and define distinct lung activities associated with the IgG that predict severe COVID-19 and protection against SARS-CoV-2. ONE SENTENCE SUMMARY Divergent early antibody responses predict COVID-19 disease trajectory and mRNA vaccine response and are functionally distinct in vivo .
Collapse
|
16
|
Kalinowski A, Liliental J, Anker LA, Linkovski O, Culbertson C, Hall JN, Pattni R, Sabatti C, Noordsy D, Hallmayer JF, Mellins ED, Ballon JS, O'Hara R, Levinson DF, Urban AE. Increased activation product of complement 4 protein in plasma of individuals with schizophrenia. Transl Psychiatry 2021; 11:486. [PMID: 34552056 PMCID: PMC8458380 DOI: 10.1038/s41398-021-01583-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 07/28/2021] [Accepted: 08/17/2021] [Indexed: 02/08/2023] Open
Abstract
Structural variation in the complement 4 gene (C4) confers genetic risk for schizophrenia. The variation includes numbers of the increased C4A copy number, which predicts increased C4A mRNA expression. C4-anaphylatoxin (C4-ana) is a C4 protein fragment released upon C4 protein activation that has the potential to change the blood-brain barrier (BBB). We hypothesized that elevated plasma levels of C4-ana occur in individuals with schizophrenia (iSCZ). Blood was collected from 15 iSCZ with illness duration < 5 years and from 14 healthy controls (HC). Plasma C4-ana was measured by radioimmunoassay. Other complement activation products C3-ana, C5-ana, and terminal complement complex (TCC) were also measured. Digital-droplet PCR was used to determine C4 gene structural variation state. Recombinant C4-ana was added to primary brain endothelial cells (BEC) and permeability was measured in vitro. C4-ana concentration was elevated in plasma from iSCZ compared to HC (mean = 654 ± 16 ng/mL, 557 ± 94 respectively, p = 0.01). The patients also carried more copies of the C4AL gene and demonstrated a positive correlation between plasma C4-ana concentrations and C4A gene copy number. Furthermore, C4-ana increased the permeability of a monolayer of BEC in vitro. Our findings are consistent with a specific role for C4A protein in schizophrenia and raise the possibility that its activation product, C4-ana, increases BBB permeability. Exploratory analyses suggest the novel hypothesis that the relationship between C4-ana levels and C4A gene copy number could also be altered in iSCZ, suggesting an interaction with unknown genetic and/or environmental risk factors.
Collapse
Affiliation(s)
- Agnieszka Kalinowski
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA.
- Sierra Pacific Mental Illness Research Education and Clinical Center (MIRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA.
| | - Joanna Liliental
- Translational Applications Service Center, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Translational Research and Applied Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Lauren A Anker
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Sierra Pacific Mental Illness Research Education and Clinical Center (MIRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - Omer Linkovski
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel
| | - Collin Culbertson
- Department of Neurology, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Jacob N Hall
- Department of Neurology, Stanford University School of Medicine, Stanford, CA, 94305, USA
- The Neurology Center of Southern California, Temecula, CA, 92592, USA
| | - Reenal Pattni
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Department of Genetics, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Chiara Sabatti
- Department of Biomedical Data Science and Statistics, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Douglas Noordsy
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Joachim F Hallmayer
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Sierra Pacific Mental Illness Research Education and Clinical Center (MIRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - Elizabeth D Mellins
- Department of Pediatrics, Stanford Program in Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Jacob S Ballon
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Ruth O'Hara
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA
- Sierra Pacific Mental Illness Research Education and Clinical Center (MIRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - Douglas F Levinson
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Alexander E Urban
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA.
- Department of Genetics, Stanford University School of Medicine, Stanford, CA, 94305, USA.
| |
Collapse
|
17
|
Liu R, Jiang W, Mellins ED. Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA). Cell Mol Immunol 2021; 18:1847-1860. [PMID: 34117370 PMCID: PMC8193015 DOI: 10.1038/s41423-021-00717-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 05/25/2021] [Indexed: 11/12/2022] Open
Abstract
CD4+ T cells orchestrate adaptive immune responses via binding of antigens to their receptors through specific peptide/MHC-II complexes. To study these responses, it is essential to identify protein-derived MHC-II peptide ligands that constitute epitopes for T cell recognition. However, generating cells expressing single MHC-II alleles and isolating these proteins for use in peptide elution or binding studies is time consuming. Here, we express human MHC alleles (HLA-DR4 and HLA-DQ6) as native, noncovalent αβ dimers on yeast cells for direct flow cytometry-based screening of peptide ligands from selected antigens. We demonstrate rapid, accurate identification of DQ6 ligands from pre-pro-hypocretin, a narcolepsy-related immunogenic target. We also identify 20 DR4-binding SARS-CoV-2 spike peptides homologous to SARS-CoV-1 epitopes, and one spike peptide overlapping with the reported SARS-CoV-2 epitope recognized by CD4+ T cells from unexposed individuals carrying DR4 subtypes. Our method is optimized for immediate application upon the emergence of novel pathogens.
Collapse
Affiliation(s)
- Rongzeng Liu
- Department of Pediatrics-Human Gene Therapy, Stanford University School of Medicine, Stanford, CA, USA
- Stanford Immunology, Stanford University School of Medicine, Stanford, CA, USA
- Department of Immunology, Henan University of Science and Technology School of Medicine, Luoyang, China
| | - Wei Jiang
- Department of Pediatrics-Human Gene Therapy, Stanford University School of Medicine, Stanford, CA, USA.
- Stanford Immunology, Stanford University School of Medicine, Stanford, CA, USA.
| | - Elizabeth D Mellins
- Department of Pediatrics-Human Gene Therapy, Stanford University School of Medicine, Stanford, CA, USA.
- Stanford Immunology, Stanford University School of Medicine, Stanford, CA, USA.
| |
Collapse
|
18
|
Ghosh D, Jiang W, Mukhopadhyay D, Mellins ED. New insights into B cells as antigen presenting cells. Curr Opin Immunol 2021; 70:129-137. [PMID: 34242927 DOI: 10.1016/j.coi.2021.06.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 06/07/2021] [Accepted: 06/09/2021] [Indexed: 01/06/2023]
Abstract
In addition to their role as antibody producing cells, B cells make a critical contribution to adaptive immune responses by functioning as professional antigen-presenting cells (APC). Distinctive features of B cells as APC include the expression of the B cell receptor (BCR) for antigen and regulated expression of HLA-DO. Here, we discuss recent progress in investigation of B cells as APC. We start with an update on the canonical MHC class II antigen presentation pathway in B cells and alternative pathways, including generation of extracellular vesicles. Turning to APC function, we highlight the roles of B cells as thymic APC, as APC for T follicular helper (TFH), as APC for CD4 memory T cells and as presenters of idiotypic BCR determinants. We also note recent examples that link B cell Ag-presentation to disease. Emerging evidence indicates that, in addition to unique features of B cells compared to other professional APC, there is appreciable heterogeneity among B cells, arising from, for example, B cell activation state or the microenvironment.
Collapse
Affiliation(s)
- Debopam Ghosh
- Department of Pediatrics, Program in Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Wei Jiang
- Department of Pediatrics, Program in Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Dhriti Mukhopadhyay
- Department of Surgery, University of Arizona, Tucson, AZ 85724, USA; Tuba City Regional Health Care, Tuba City, AZ 86045, USA
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
| |
Collapse
|
19
|
Zhou X, Yu W, Lyu SC, Macaubas C, Bunning B, He Z, Mellins ED, Nadeau KC. A positive feedback loop reinforces the allergic immune response in human peanut allergy. J Exp Med 2021; 218:e20201793. [PMID: 33944900 PMCID: PMC8103542 DOI: 10.1084/jem.20201793] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Revised: 12/18/2020] [Accepted: 03/04/2021] [Indexed: 12/13/2022] Open
Abstract
Food allergies are a leading cause of anaphylaxis, and cellular mechanisms involving antigen presentation likely play key roles in their pathogenesis. However, little is known about the response of specific antigen-presenting cell (APC) subsets to food allergens in the setting of food allergies. Here, we show that in peanut-allergic humans, peanut allergen drives the differentiation of CD209+ monocyte-derived dendritic cells (DCs) and CD23+ (FcєRII) myeloid dendritic cells through the action of allergen-specific CD4+ T cells. CD209+ DCs act reciprocally on the same peanut-specific CD4+ T cell population to reinforce Th2 cytokine expression in a positive feedback loop, which may explain the persistence of established food allergy. In support of this novel model, we show clinically that the initiation of oral immunotherapy (OIT) in peanut-allergic patients is associated with a decrease in CD209+ DCs, suggesting that breaking the cycle of positive feedback is associated with therapeutic effect.
Collapse
Affiliation(s)
- Xiaoying Zhou
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University and Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford, CA
| | - Wong Yu
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University and Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford, CA
| | - Shu-Chen Lyu
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University and Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford, CA
| | - Claudia Macaubas
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA
| | - Bryan Bunning
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University and Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford, CA
| | - Ziyuan He
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University and Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford, CA
| | - Elizabeth D. Mellins
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA
| | - Kari C. Nadeau
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University and Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford, CA
| |
Collapse
|
20
|
Vallania F, Zisman L, Macaubas C, Hung SC, Rajasekaran N, Mason S, Graf J, Nakamura M, Mellins ED, Khatri P. Multicohort Analysis Identifies Monocyte Gene Signatures to Accurately Monitor Subset-Specific Changes in Human Diseases. Front Immunol 2021; 12:659255. [PMID: 34054824 PMCID: PMC8160521 DOI: 10.3389/fimmu.2021.659255] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 04/26/2021] [Indexed: 12/12/2022] Open
Abstract
Monocytes are crucial regulators of inflammation, and are characterized by three distinct subsets in humans, of which classical and non-classical are the most abundant. Different subsets carry out different functions and have been previously associated with multiple inflammatory conditions. Dissecting the contribution of different monocyte subsets to disease is currently limited by samples and cohorts, often resulting in underpowered studies and poor reproducibility. Publicly available transcriptome profiles provide an alternative source of data characterized by high statistical power and real-world heterogeneity. However, most transcriptome datasets profile bulk blood or tissue samples, requiring the use of in silico approaches to quantify changes in cell levels. Here, we integrated 853 publicly available microarray expression profiles of sorted human monocyte subsets from 45 independent studies to identify robust and parsimonious gene expression signatures, consisting of 10 genes specific to each subset. These signatures maintain their accuracy regardless of disease state in an independent cohort profiled by RNA-sequencing and are specific to their respective subset when compared to other immune cells from both myeloid and lymphoid lineages profiled across 6160 transcriptome profiles. Consequently, we show that these signatures can be used to quantify changes in monocyte subsets levels in expression profiles from patients in clinical trials. Finally, we show that proteins encoded by our signature genes can be used in cytometry-based assays to specifically sort monocyte subsets. Our results demonstrate the robustness, versatility, and utility of our computational approach and provide a framework for the discovery of new cellular markers.
Collapse
Affiliation(s)
- Francesco Vallania
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, United States.,Center for Biomedical Research, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, United States
| | - Liron Zisman
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, United States.,Center for Biomedical Research, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, United States.,Department of Pediatrics, Program in Immunology, School of Medicine, Stanford University, Stanford, CA, United States
| | - Claudia Macaubas
- Department of Pediatrics, Program in Immunology, School of Medicine, Stanford University, Stanford, CA, United States
| | - Shu-Chen Hung
- Department of Pediatrics, Program in Immunology, School of Medicine, Stanford University, Stanford, CA, United States
| | - Narendiran Rajasekaran
- Department of Pediatrics, Program in Immunology, School of Medicine, Stanford University, Stanford, CA, United States
| | - Sonia Mason
- Department of Pediatrics, Program in Immunology, School of Medicine, Stanford University, Stanford, CA, United States
| | - Jonathan Graf
- Department of Medicine, University of California San Francisco, San Francisco, CA, United States
| | - Mary Nakamura
- Department of Medicine, University of California San Francisco, San Francisco, CA, United States
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, School of Medicine, Stanford University, Stanford, CA, United States
| | - Purvesh Khatri
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, United States.,Center for Biomedical Research, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, United States
| |
Collapse
|
21
|
Abstract
Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease affecting the joints and other organs that occurs in 1 in 1,000 children in the United States. Given the various categories of JIA, interpretation of the literature can be difficult. In this review, new developments in understanding non-systemic JIA and its treatment will be covered. Recent advances in the journey toward personalized treatment in JIA will be highlighted, including a review of currently available biologic modifiers. Uveitis and the temporomandibular joint will be discussed as particularly challenging treatment issues. Recent guideline updates and literature-guided treatment decisions will be reviewed.
Collapse
Affiliation(s)
- John M Bridges
- Children’s of Alabama/University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, California, USA
| | - Randy Q Cron
- Children’s of Alabama/University of Alabama at Birmingham, Birmingham, Alabama, USA
| |
Collapse
|
22
|
Zisman D, Samad A, Ardoin SP, Chira P, White P, Lavi I, von Scheven E, Lawson EF, Hing M, Mellins ED. US Adult Rheumatologists' Perspectives on the Transition Process for Young Adults With Rheumatic Conditions. Arthritis Care Res (Hoboken) 2020; 72:432-440. [PMID: 30740937 DOI: 10.1002/acr.23845] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Accepted: 02/05/2019] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To assess the attitudes and common practices of adult rheumatologists in the US regarding health care transition (HCT) for young adults with rheumatic diseases. METHODS An anonymous online survey was sent to US adult rheumatologist members of the American College of Rheumatology to collect demographic data and information on attitudes and common practices regarding the transition process. RESULTS Of 4,064 contacted rheumatologists, 203 (5%) completed the survey. Almost half of respondents (45.1%) were never trained in transition practices, and 74.7% were not familiar with the American Academy of Pediatrics/American Academy of Family Physicians/American College of Physicians Consensus Statement About Transitions for Youth with Special Healthcare Needs. Only 56.2% felt comfortable caring for former pediatric patients. The vast majority of respondents (90.7%) did not have a multidisciplinary transition team, and 37% did not have a plan for transitioning pediatric patients into their practice. Most adult rheumatologists were unsatisfied with the current transition process (92.9%), due to insufficient resources, personnel (91.1%), and time in clinic (86.9%). They also were unsatisfied with referral data received concerning previous treatments (48.9%), hospitalization history (48%), disease activity index (45.1%), medical history summary (43.9%), comorbidities (36.4%), medication list (34.1%), and disease classification (32.6%). Three major barriers to HCT were lack of insurance reimbursement (33.7%), knowledge about community resources (30.8%), and lapses in care between primary provider and specialist (27.8%). CONCLUSION This survey identified substantial gaps in knowledge and resources regarding HCT for young adults with rheumatic diseases. These may be best addressed by further training, research, dedicated resources, adequate payment, and practice guidelines.
Collapse
Affiliation(s)
- Devy Zisman
- Carmel Medical Center and Technion, Haifa, Israel
| | - Aaida Samad
- Case Western Reserve University, Cleveland, Ohio
| | | | | | | | - Idit Lavi
- Carmel Medical Center, Haifa, Israel
| | | | | | | | | |
Collapse
|
23
|
Ding S, Song Y, Brulois KF, Pan J, Co JY, Ren L, Feng N, Yasukawa LL, Sánchez-Tacuba L, Wosen JE, Mellins ED, Monack DM, Amieva MR, Kuo CJ, Butcher EC, Greenberg HB. Retinoic Acid and Lymphotoxin Signaling Promote Differentiation of Human Intestinal M Cells. Gastroenterology 2020; 159:214-226.e1. [PMID: 32247021 PMCID: PMC7569531 DOI: 10.1053/j.gastro.2020.03.053] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 03/12/2020] [Accepted: 03/20/2020] [Indexed: 01/11/2023]
Abstract
BACKGROUND & AIMS Intestinal microfold (M) cells are a unique subset of intestinal epithelial cells in the Peyer's patches that regulate mucosal immunity, serving as portals for sampling and uptake of luminal antigens. The inability to efficiently develop human M cells in cell culture has impeded studies of the intestinal immune system. We aimed to identify signaling pathways required for differentiation of human M cells and establish a robust culture system using human ileum enteroids. METHODS We analyzed transcriptome data from mouse Peyer's patches to identify cell populations in close proximity to M cells. We used the human enteroid system to determine which cytokines were required to induce M-cell differentiation. We performed transcriptome, immunofluorescence, scanning electron microscope, and transcytosis experiments to validate the development of phenotypic and functional human M cells. RESULTS A combination of retinoic acid and lymphotoxin induced differentiation of glycoprotein 2-positive human M cells, which lack apical microvilli structure. Upregulated expression of innate immune-related genes within M cells correlated with a lack of viral antigens after rotavirus infection. Human M cells, developed in the enteroid system, internalized and transported enteric viruses, such as rotavirus and reovirus, across the intestinal epithelium barrier in the enteroids. CONCLUSIONS We identified signaling pathways required for differentiation of intestinal M cells, and used this information to create a robust culture method to develop human M cells with capacity for internalization and transport of viruses. Studies of this model might increase our understanding of antigen presentation and the systemic entry of enteric pathogens in the human intestine.
Collapse
Affiliation(s)
- Siyuan Ding
- Department of Molecular Microbiology, Washington University School of Medicine, St Louis, Missouri.
| | - Yanhua Song
- Palo Alto Veterans Institute of Research, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA,Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA 94305, USA,Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA,Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China
| | - Kevin F. Brulois
- Palo Alto Veterans Institute of Research, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA,Department of Pathology, Stanford University, Stanford, CA 94305, USA
| | - Junliang Pan
- Palo Alto Veterans Institute of Research, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA,Department of Pathology, Stanford University, Stanford, CA 94305, USA
| | - Julia Y. Co
- Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA,Department of Pediatrics, Stanford University, Stanford, CA 94305, USA
| | - Lili Ren
- School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, China
| | - Ningguo Feng
- Palo Alto Veterans Institute of Research, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA,Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA 94305, USA,Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
| | - Linda L. Yasukawa
- Palo Alto Veterans Institute of Research, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA,Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA 94305, USA,Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
| | - Liliana Sánchez-Tacuba
- Palo Alto Veterans Institute of Research, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA,Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA 94305, USA,Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
| | - Jonathan E. Wosen
- Department of Pediatrics, Stanford University, Stanford, CA 94305, USA
| | | | - Denise M. Monack
- Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
| | - Manuel R. Amieva
- Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA,Department of Pediatrics, Stanford University, Stanford, CA 94305, USA
| | - Calvin J. Kuo
- Department of Medicine, Division of Hematology, Stanford University, Stanford, CA 94305, USA
| | - Eugene C. Butcher
- Palo Alto Veterans Institute of Research, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA,Department of Pathology, Stanford University, Stanford, CA 94305, USA
| | - Harry B. Greenberg
- Palo Alto Veterans Institute of Research, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA,Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA 94305, USA,Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
| |
Collapse
|
24
|
Maller J, Fox E, Park KT, Paul SS, Baszis K, Borocco C, Prahalad S, Quartier P, Reinhardt A, Schonenberg-Meinema D, Shipman-Duensing L, Terreri MT, Simard J, Lavi I, Chalom E, Hsu J, Zisman D, Mellins ED. Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. J Rheumatol 2020; 48:567-574. [PMID: 32541073 DOI: 10.3899/jrheum.200230] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/28/2020] [Indexed: 12/21/2022]
Abstract
OBJECTIVE The incidence of inflammatory bowel disease (IBD) in juvenile idiopathic arthritis (JIA) is higher than in the general pediatric population. However, reports of IBD in the systemic JIA (sJIA) subtype are limited. We sought to characterize sJIA patients diagnosed with IBD and to identify potential contributing risk factors. METHODS Using an internationally distributed survey, we identified 16 patients with sJIA who were subsequently diagnosed with IBD (sJIA-IBD cohort). Five hundred twenty-two sJIA patients without IBD were identified from the CARRA Legacy Registry and served as the sJIA-only cohort for comparison. Differences in demographic, clinical characteristics, and therapy were assessed using chi-square test, Fisher exact test, t-test, and univariate and multivariate logistic regression, as appropriate. RESULTS Of the patients with sJIA-IBD, 75% had a persistent sJIA course and 25% had a history of macrophage activation syndrome. sJIA-IBD subjects were older at sJIA diagnosis, more often non-White, had a higher rate of IBD family history, and were more frequently treated with etanercept or canakinumab compared to sJIA-only subjects. Sixty-nine percent of sJIA-IBD patients successfully discontinued sJIA medications following IBD diagnosis, and sJIA symptoms resolved in 9 of 12 patients treated with tumor necrosis factor-α (TNF-α) inhibitors. CONCLUSION IBD in the setting of sJIA is a rare occurrence. The favorable response of sJIA symptoms to therapeutic TNF-α inhibition suggests that the sJIA-IBD cohort may represent a mechanistically distinct sJIA subgroup. Our study highlights the importance of maintaining a high level of suspicion for IBD when gastrointestinal involvement occurs in patients with sJIA and the likely broad benefit of TNF-α inhibition in those cases.
Collapse
Affiliation(s)
- Justine Maller
- J. Maller, MD, PhD, Department of Pediatrics, Division of Rheumatology, Stanford University School of Medicine, Stanford, California, USA
| | - Emily Fox
- E. Fox, MD, Department of Pediatrics, Division of Rheumatology, Stanford University School of Medicine, Stanford, California, and Department of Pediatrics, Division of Rheumatology, Children's Mercy Hospital, University of Missouri-Kansas City, Kansas City, Missouri, USA
| | - K T Park
- K.T. Park, MD, Department of Pediatrics, Division of Gastroenterology, Stanford University School of Medicine, Stanford, California, USA
| | - Sarah Sertial Paul
- S. Sertial Paul, DO, Department of Pediatrics, Goryeb Children's Hospital, Morristown, New Jersey, USA
| | - Kevin Baszis
- K. Baszis, MD, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Charlotte Borocco
- C. Borocco, MD, Paris University, Imagine Institute and Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital, AP-HP, Paris, France
| | - Sampath Prahalad
- S. Prahalad, MD, Department of Pediatrics and Department of Genetics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Pierre Quartier
- P. Quartier, MD, Paris University, Imagine Institute, RAISE Reference Centre and Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital, AP-HP, Paris, France
| | - Adam Reinhardt
- A. Reinhardt, MD, Department of Pediatrics, Boys Town National Research Hospital, Omaha, Nebraska, USA
| | - Dieneke Schonenberg-Meinema
- D. Schonenberg-Meinema, MD, Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Amsterdam Universitair Medische Centra, Amsterdam, the Netherlands
| | - Lauren Shipman-Duensing
- L. Shipman-Duensing, MD, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Maria Teresa Terreri
- M.T. Terreri, MD, Department of Pediatrics, Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil
| | - Julia Simard
- J. Simard, ScD, Department of Health Research & Policy, Division of Epidemiology, and Department of Medicine, Division of Immunology & Rheumatology, Stanford University, Stanford, California, USA
| | - Idit Lavi
- I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel
| | - Elizabeth Chalom
- E. Chalom, MD, Department of Pediatrics, Saint Barnabas Medical Center, Livingston, New Jersey, USA
| | - Joyce Hsu
- J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA
| | - Devy Zisman
- D. Zisman, MD, Carmel Medical Center, Rheumatology Unit, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Elizabeth D Mellins
- E.D. Mellins, MD, Department of Pediatrics, Division of Human Gene Therapy, Program in Immunology, Stanford University School of Medicine, Stanford, California, USA.
| | | |
Collapse
|
25
|
Jiang W, Birtley JR, Hung SC, Wang W, Chiou SH, Davis MM, Stern LJ, Mellins ED. Hemagglutinin as potential in vivo driver of DQ6-restricted clonal expansion of CD4+ T cells cross-reactive with hypocretin in narcolepsy. The Journal of Immunology 2020. [DOI: 10.4049/jimmunol.204.supp.224.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Narcolepsy is a sleeping disorder, caused by selective loss of neurons secreting a wake-promoting hormone, hypocretin (HCRT). Increased narcolepsy incidence was noted in China after the peak of 2009 H1N1 pandemic influenza (pH1N1) cases and in Europe after Pandemrix vaccine administration. The causes of HCRT neuron depletion and its relationship with pH1N1 are unknown. As narcolepsy susceptibility is associated with HLA-DQ6 and with a TCR α gene (J24) polymorphism, we hypothesized that abnormally expanded J24+/CD4+ T cells in DQ6+ subjects mediate autoimmunity against HCRT neurons and that molecular mimicry (epitopes in pH1N1 and self-antigens) drives T cell expansion via DQ6 presentation. We reported the in vivo expansion of DQ6/HCRT87–97–reactive J24+/CD4+ clones using a J24 allele and an un-conventional phenotype in patients compared to related clones in DQ6+ controls. Here, DQ6/peptide binding and crystal structure identify an epitope, HA274–287 from pH1N1 hemagglutinin, with homology to HCRT87–97 and another peptide, HCRT1–13. DQ6/HA274–287 tetramers isolated >2000 tetramer+/CD4+ T cells in DQ6+ subjects. Single-cell sequencing of TCRs and 25 phenotypic transcripts identify a DQ6/HA274–287 tetramer+/J24+ clone with the identical TCR clonotype (TCR27) and phenotype as the expanded DQ6/HCRT87–97–reactive J24+ clones previously found in the same patient. Control-derived TCR27+ clones identified by DQ6/HCRT1–13 or DQ6/HCRT25–37 tetramers are unexpanded and lack expression of any of the phenotypic genes. Our findings show that DQ6+ subjects carry J24+/CD4+ cells, both public and cross-reactive (e.g TCR27). TCR27 expansion in patients argues for molecular mimicry as a factor in narcolepsy immunopathogenesis.
Collapse
Affiliation(s)
- Wei Jiang
- 1Stanford University School of Medicine
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Ghosh D, Pham TD, He X, O’mara ME, Kantor AB, Nguyen K, Sengupta D, Eisenlohr LC, Jensen PE, Herzenberg LA, Boyd SD, Ghosn EE, Mellins ED. The class II peptide editor, H2-M, affects the development and repertoire of B-1 cells. The Journal of Immunology 2020. [DOI: 10.4049/jimmunol.204.supp.153.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Non-classical major histocompatibility complex class-II (MHCII) protein H2-M edits peptides bound to conventional MHCII (pMHCII) in favor of stable pMHCII complexes. Although the impact of H2-M deficiency on pMHCII expression and T cell activation is well-studied, information on how this protein affects the development and phenotypic profile of APCs is lacking. We found that the absence of H2-M in C57BL/6 (B6) mice, resulted in a loss of surface expression and peptide-cargo of MHCII molecules in B cells across lymphoid organs. Lower pMHCII expression reduced MHCII association with BCR, affecting the integrated BCR signaling. Importantly, in H2-M deficient B6 mice, compared to the wildtype mice, frequency and abundance of B-1 cells, but not conventional B-2 cells, was reduced in the spleen and peritoneum. This H2-M mediated effect on the B-1 cell population was only evident in the B6 background (I-Ab), but not in BALB/c (I-Ad/I-Ed), indicating an MHCII haplotype-dependent phenomenon. A decrease in B-1 cell number also was evident in immature B-1 cells, emphasizing that H2-M deficiency affects B-1 cell development. In H2-M KO mice compared to WT B6, B-1 cells display a significantly lower self-renewal capacity and a higher rate of apoptosis. Furthermore, H2-M deficiency alters the B-1 BCR repertoire, selecting for B-1 cells specific for highly abundant epitopes, but not for low-frequency epitopes. Collectively, these data identify the impact of H2-M/MHCII interaction as a regulator of BCR signaling that influences the selection, maturation, and maintenance of mature B-1 cell clones in the periphery.
Collapse
Affiliation(s)
| | | | - Xiao He
- 3University of Utah, Department of Pathology
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Saper VE, Chen G, Guillerman RP, Khatri P, Cron RQ, Mellins ED. Response to: 'Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato et al. Ann Rheum Dis 2020; 81:e62. [PMID: 32317313 DOI: 10.1136/annrheumdis-2020-217426] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Accepted: 04/07/2020] [Indexed: 11/03/2022]
Affiliation(s)
- Vivian E Saper
- Department of Pediatrics, Stanford University, Stanford, CA, USA
| | - Guangbo Chen
- Institute for Immunity, Transplantation and Infection, Center for Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, California, USA
| | - R Paul Guillerman
- Department of Pediatric Radiology, Texas Children's Hospital, Houston, Texas, USA
| | - Purvesh Khatri
- Institute for Immunity, Transplantation and Infection, Center for Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, California, USA
| | - Randy Q Cron
- Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USA
| |
Collapse
|
28
|
Stoll ML, Mellins ED. Psoriatic arthritis in childhood: A commentary on the controversy. Clin Immunol 2020; 214:108396. [PMID: 32229291 DOI: 10.1016/j.clim.2020.108396] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 03/24/2020] [Accepted: 03/25/2020] [Indexed: 12/28/2022]
Abstract
Approximately 5% of children with juvenile idiopathic arthritis (JIA) are diagnosed with the psoriatic form of the disease. In recent years, there has been substantial scholarship demonstrating both heterogeneity within the disease as well as similarities with other forms of JIA, culminating in a recent proposal for the categorization of JIA that excluded the psoriatic form altogether. The purpose of the review is to summarize the clinical, epidemiologic, and genetic features of psoriatic JIA (PsJIA), comparing it with other categories of JIA including spondyloarthritis. We conclude that there are sufficient unique clinical and genetic features within PsJIA as well as similarities with its adult counterpart that warrant including it within the JIA paradigm.
Collapse
Affiliation(s)
- Matthew L Stoll
- Department of Pediatrics, University of Alabama at Birmingham, 1600 7(th) Avenue South, Children's Park Place North Suite G10, Birmingham, AL 35233, USA.
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, Stanford University, 269 Campus Drive, CCSR Rm 2105c, Stanford, CA 94305-5164, USA.
| |
Collapse
|
29
|
Abstract
Our understanding of the mechanisms underlying HLA associations with inflammatory arthritis continues to evolve. Disease associations have been refined, and interactions of HLA genotype with other genes and environmental risk factors in determining disease risk have been identified. This Review provides basic information on the genetics and molecular function of HLA molecules, as well as general features of HLA associations with disease. Evidence is discussed regarding the various peptide-dependent and peptide-independent mechanisms by which HLA alleles might contribute to the pathogenesis of three types of inflammatory arthritis: rheumatoid arthritis, spondyloarthritis and systemic juvenile idiopathic arthritis. Also discussed are HLA allelic associations that shed light on the genetic heterogeneity of inflammatory arthritides and on the relationships between adult and paediatric forms of arthritis. Clinical implications range from improved diagnosis and outcome prediction to the possibility of using HLA associations in developing personalized strategies for the treatment and prevention of these diseases.
Collapse
Affiliation(s)
- Robert Busch
- Department of Life Sciences, University of Roehampton, Whitelands College, London, UK.
| | - Simon Kollnberger
- School of Medicine, Cardiff University, UHW Main Building, Heath Park, Cardiff, UK
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, Stanford University Medical Center, Stanford, CA, USA.
| |
Collapse
|
30
|
Khatri S, Mellins ED, Torok KS, Bukhari SA, Astakhova K. Combined Assay for Detecting Autoantibodies to Nucleic Acids and Apolipoprotein H in Patients with Systemic Lupus Erythematosus. Methods Mol Biol 2020; 2063:57-71. [PMID: 31667763 DOI: 10.1007/978-1-0716-0138-9_6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The complicated clinical picture and biomolecular pattern of human autoimmune diseases (ADs) make knowledge on their etiology still fragmentary. The diagnostic approaches for ADs require improvement both for clinical and research effort to progress. Synthetic biomolecular antigens find growing applications for diagnosis and investigation of ADs. The main goal of this work is to detect interaction between synthetic antigens and autoantibodies in systemic lupus erythematosus within a combined, high-throughput assay. A panel of synthetic antigens has been prepared from DNA, RNA, locked nucleic acids and apolipoprotein H. The binding of synthetic antigens to autoantibodies has been confirmed in sera samples from those with active systemic lupus erythematosus (SLE) by indirect enzyme linked immunosorbent assay. Our study provides an efficient methodology for combined autoantibody profiling in SLE.
Collapse
Affiliation(s)
- Sangita Khatri
- Department of Chemistry, Technical University of Denmark, Kgs Lyngby, Denmark.
| | - Elizabeth D Mellins
- Program in Immunology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | - Kathryn S Torok
- Division of Rheumatology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA
| | - Syeda Atia Bukhari
- Department of Chemistry, Technical University of Denmark, Kgs Lyngby, Denmark
| | - Kira Astakhova
- Department of Chemistry, Technical University of Denmark, Kgs Lyngby, Denmark
| |
Collapse
|
31
|
Mahajan S, Mellins ED, Faccio R. Diacylglycerol Kinase ζ Regulates Macrophage Responses in Juvenile Arthritis and Cytokine Storm Syndrome Mouse Models. J Immunol 2020; 204:137-146. [PMID: 31801815 PMCID: PMC6920556 DOI: 10.4049/jimmunol.1900721] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Accepted: 11/04/2019] [Indexed: 12/18/2022]
Abstract
Dysregulation of monocyte and macrophage responses are often observed in children with systemic juvenile idiopathic arthritis (sJIA) and cytokine storm syndrome (CSS), a potentially fatal complication of chronic rheumatic diseases. Both conditions are associated with activation of TLR signaling in monocyte and macrophage lineage cells, leading to overwhelming inflammatory responses. Despite the importance of TLR engagement in activating proinflammatory macrophages, relatively little is known about activation of intrinsic negative regulatory pathways to attenuate excessive inflammatory responses. In this study, we demonstrate that loss of diacylglycerol (DAG) kinase (Dgk) ζ, an enzyme which converts DAG into phosphatidic acid, limits inflammatory cytokine production in an arthritic mouse model dependent on TLR2 signaling and in a CSS mouse model dependent on TLR9 signaling. In vitro, Dgkζ deficiency results in reduced production of TNF-α, IL-6, and IL-1β and in limited M1 macrophage polarization. Mechanistically, Dgkζ deficiency decreases STAT1 and STAT3 phosphorylation. Moreover, Dgkζ levels are increased in macrophages derived from mice with CSS or exposed to plasma from sJIA patients with active disease. Our data suggest that Dgkζ induction in arthritic conditions perpetuates systemic inflammatory responses mediated by macrophages and highlight a potential role of Dgkζ-DAG/phosphatidic acid axis as a modulator of inflammatory cytokine production in sJIA and CSS.
Collapse
Affiliation(s)
- Sahil Mahajan
- Department of Orthopedic Surgery, Musculoskeletal Research Center, Washington University School of Medicine, St. Louis, MO 63110
| | - Elizabeth D Mellins
- Program in Immunology and Allergy, Department of Pediatrics, Stanford University, Stanford, CA 94305; and
| | - Roberta Faccio
- Department of Orthopedic Surgery, Musculoskeletal Research Center, Washington University School of Medicine, St. Louis, MO 63110;
- Shriners Hospitals for Children, St. Louis, MO 63110
| |
Collapse
|
32
|
Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, Canna S, Schulert G, Deterding R, Xu J, Leung AN, Bouzoubaa L, Abulaban K, Baszis K, Behrens EM, Birmingham J, Casey A, Cidon M, Cron RQ, De A, De Benedetti F, Ferguson I, Fishman MP, Goodman SI, Graham TB, Grom AA, Haines K, Hazen M, Henderson LA, Ho A, Ibarra M, Inman CJ, Jerath R, Khawaja K, Kingsbury DJ, Klein-Gitelman M, Lai K, Lapidus S, Lin C, Lin J, Liptzin DR, Milojevic D, Mombourquette J, Onel K, Ozen S, Perez M, Phillippi K, Prahalad S, Radhakrishna S, Reinhardt A, Riskalla M, Rosenwasser N, Roth J, Schneider R, Schonenberg-Meinema D, Shenoi S, Smith JA, Sönmez HE, Stoll ML, Towe C, Vargas SO, Vehe RK, Young LR, Yang J, Desai T, Balise R, Lu Y, Tian L, Bejerano G, Davis MM, Khatri P, Mellins ED. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 2019; 78:1722-1731. [PMID: 31562126 PMCID: PMC7065839 DOI: 10.1136/annrheumdis-2019-216040] [Citation(s) in RCA: 106] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 09/11/2019] [Accepted: 09/13/2019] [Indexed: 12/20/2022]
Abstract
OBJECTIVE To investigate the characteristics and risk factors of a novel parenchymal lung disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA). METHODS In a multicentre retrospective study, 61 cases were investigated using physician-reported clinical information and centralised analyses of radiological, pathological and genetic data. RESULTS LD was associated with distinctive features, including acute erythematous clubbing and a high frequency of anaphylactic reactions to the interleukin (IL)-6 inhibitor, tocilizumab. Serum ferritin elevation and/or significant lymphopaenia preceded LD detection. The most prevalent chest CT pattern was septal thickening, involving the periphery of multiple lobes ± ground-glass opacities. The predominant pathology (23 of 36) was pulmonary alveolar proteinosis and/or endogenous lipoid pneumonia (PAP/ELP), with atypical features including regional involvement and concomitant vascular changes. Apparent severe delayed drug hypersensitivity occurred in some cases. The 5-year survival was 42%. Whole exome sequencing (20 of 61) did not identify a novel monogenic defect or likely causal PAP-related or macrophage activation syndrome (MAS)-related mutations. Trisomy 21 and young sJIA onset increased LD risk. Exposure to IL-1 and IL-6 inhibitors (46 of 61) was associated with multiple LD features. By several indicators, severity of sJIA was comparable in drug-exposed subjects and published sJIA cohorts. MAS at sJIA onset was increased in the drug-exposed, but was not associated with LD features. CONCLUSIONS A rare, life-threatening lung disease in sJIA is defined by a constellation of unusual clinical characteristics. The pathology, a PAP/ELP variant, suggests macrophage dysfunction. Inhibitor exposure may promote LD, independent of sJIA severity, in a small subset of treated patients. Treatment/prevention strategies are needed.
Collapse
Affiliation(s)
- Vivian E Saper
- Pediatrics, Stanford University, Stanford, California, USA
| | - Guangbo Chen
- Institute for Immunity, Transplantation and Infection, Center for Biomedical Informatics Research, Medicine, Stanford University, Stanford, California, USA
| | - Gail H Deutsch
- Pathology, Seattle Children's Hospital, Seattle, Washington, USA
- University of Washington School of Medicine, Seattle, Washington, USA
| | | | | | | | - Scott Canna
- Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Grant Schulert
- Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - Robin Deterding
- Children's Hospital Colorado, Aurora, Colorado, USA
- University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Jianpeng Xu
- Pediatrics, Stanford University, Stanford, California, USA
| | - Ann N Leung
- Radiology, Stanford University, Stanford, California, USA
| | - Layla Bouzoubaa
- Public Health Services, Biostatistics, University of Miami School of Medicine, Miami, Florida, USA
| | - Khalid Abulaban
- Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA
- Michigan State University, East Lansing, Michigan, USA
| | - Kevin Baszis
- Pediatrics, Washington University in Saint Louis, Saint Louis, Missouri, USA
| | - Edward M Behrens
- Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - James Birmingham
- Medicine, Metro Health Hospital, Wyoming, Michigan, USA
- University of Michigan, Ann Arbor, Michigan, USA
| | - Alicia Casey
- Boston Children's Hospital, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - Michal Cidon
- Pediatrics, Children's Hospital of Los Angeles, Los Angeles, California, USA
- University of Southern California, Los Angeles, California, USA
| | - Randy Q Cron
- Children's of Alabama, Birmingham, Alabama, USA
- University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Aliva De
- Pediatrics, Columbia University Medical Center, New York, New York, USA
| | | | - Ian Ferguson
- Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Martha P Fishman
- Boston Children's Hospital, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - Steven I Goodman
- Arthritis Associates of South Florida, Delray Beach, Florida, USA
| | - T Brent Graham
- Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Alexei A Grom
- Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - Kathleen Haines
- Joseph M Sanzari Children's Hospital, Hackensack, New Jersey, USA
- Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Melissa Hazen
- Boston Children's Hospital, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - Lauren A Henderson
- Boston Children's Hospital, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - Assunta Ho
- Pediatrics, Prince of Wales Hospital, New Territories, Hong Kong
- Faculty of Medicine, Chinese University of Hong Kong, New Territories, Hong Kong
| | - Maria Ibarra
- Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA
- School of Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA
| | - Christi J Inman
- Pediatrics, University of Utah Health Sciences Center, Salt Lake City, Utah, USA
| | - Rita Jerath
- Children's Hospital of Georgia, Augusta, Georgia, USA
- Augusta University, Augusta, Georgia, USA
| | - Khulood Khawaja
- Pediatrics, Al Mafraq Hospital, Abu Dhabi, Abu Dhabi, United Arab Emirates
| | | | - Marisa Klein-Gitelman
- Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Khanh Lai
- Pediatrics, University of Utah Health Sciences Center, Salt Lake City, Utah, USA
| | - Sivia Lapidus
- Joseph M Sanzari Children's Hospital, Hackensack, New Jersey, USA
- Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Clara Lin
- Children's Hospital Colorado, Aurora, Colorado, USA
- University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Jenny Lin
- Children's Hospital at Montefiore, Bronx, New York, USA
- Yeshiva University Albert Einstein College of Medicine, Bronx, New York, USA
| | - Deborah R Liptzin
- Children's Hospital Colorado, Aurora, Colorado, USA
- University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Diana Milojevic
- Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, USA
| | - Joy Mombourquette
- Pediatrics, Kaiser Permanente Roseville Medical Center, Roseville, California, USA
| | - Karen Onel
- Pediatrics, Hospital for Special Surgery, New York, New York, USA
- Weill Cornell Medical College, New York, New York, USA
| | - Seza Ozen
- Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - Maria Perez
- Cook Children's Medical Center, Fort Worth, Texas, USA
| | - Kathryn Phillippi
- Akron Children's Hospital, Akron, Ohio, USA
- Northeast Ohio Medical University, Rootstown, Ohio, USA
| | - Sampath Prahalad
- Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
- Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Suhas Radhakrishna
- Rady Children's Hospital, San Diego, California, USA
- Pediatrics, University of California San Diego, La Jolla, California, USA
| | - Adam Reinhardt
- Pediatrics, University of Nebraska Medical Center College of Medicine, Omaha, Nebraska, USA
| | - Mona Riskalla
- Pediatrics, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA
- University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA
| | - Natalie Rosenwasser
- Pediatrics, Hospital for Special Surgery, New York, New York, USA
- Weill Cornell Medical College, New York, New York, USA
| | - Johannes Roth
- Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
| | - Rayfel Schneider
- Hospital for Sick Children, Toronto, Ontario, Canada
- Pediatrics, University of Toronto, Toronto, Ontario, Canada
| | - Dieneke Schonenberg-Meinema
- Emma Children's Hospital AMC, Amsterdam, The Netherlands
- University of Amsterdam, Amsterdam, Noord-Holland, The Netherlands
| | - Susan Shenoi
- University of Washington School of Medicine, Seattle, Washington, USA
- Pediatrics, Seattle Children's Hospital, Seattle, Washington, USA
| | - Judith A Smith
- Pediatrics, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA
| | | | - Matthew L Stoll
- Children's of Alabama, Birmingham, Alabama, USA
- University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Christopher Towe
- Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - Sara O Vargas
- Harvard Medical School, Boston, Massachusetts, USA
- Pathology, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Richard K Vehe
- Pediatrics, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA
- University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA
| | - Lisa R Young
- Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Jacqueline Yang
- Institute for Immunity, Transplantation and Infection, Center for Biomedical Informatics Research, Medicine, Stanford University, Stanford, California, USA
| | - Tushar Desai
- Medicine, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA
| | - Raymond Balise
- Public Health Services, Biostatistics, University of Miami School of Medicine, Miami, Florida, USA
| | - Ying Lu
- Biomedical Data Science, Stanford University, Stanford, California, USA
| | - Lu Tian
- Biomedical Data Science, Stanford University, Stanford, California, USA
| | - Gill Bejerano
- Genetics, Stanford University, Stanford, California, USA
| | - Mark M Davis
- Institute for Immunity, Transplantation and Infection, Microbiology and Immunology, Stanford University, Stanford, California, USA
| | - Purvesh Khatri
- Institute for Immunity, Transplantation and Infection, Center for Biomedical Informatics Research, Medicine, Stanford University, Stanford, California, USA
| | | |
Collapse
|
33
|
Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, Husami A, Watts A, Brunner HI, Huggins J, Mellins ED, Morgan EM, Ting T, Trapnell BC, Wikenheiser-Brokamp KA, Towe C, Grom AA. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol 2019; 71:1943-1954. [PMID: 31379071 DOI: 10.1002/art.41073] [Citation(s) in RCA: 110] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Accepted: 08/01/2019] [Indexed: 12/31/2022]
Abstract
OBJECTIVE Systemic juvenile idiopathic arthritis (JIA) is associated with a recently recognized, albeit poorly defined and characterized, lung disease (LD). The objective of this study was to describe the clinical characteristics, risk factors, and histopathologic and immunologic features of this novel inflammatory LD associated with systemic JIA (designated SJIA-LD). METHODS Clinical data collected since 2010 were abstracted from the medical records of patients with systemic JIA from the Cincinnati Children's Hospital Medical Center. Epidemiologic, cellular, biochemical, genomic, and transcriptional profiling analyses were performed. RESULTS Eighteen patients with SJIA-LD were identified. Radiographic findings included diffuse ground-glass opacities, subpleural reticulation, interlobular septal thickening, and lymphadenopathy. Pathologic findings included patchy, but extensive, lymphoplasmacytic infiltrates and mixed features of pulmonary alveolar proteinosis (PAP) and endogenous lipoid pneumonia. Compared to systemic JIA patients without LD, those with SJIA-LD were younger at the diagnosis of systemic JIA (odds ratio [OR] 6.5, P = 0.007), more often had prior episodes of macrophage activation syndrome (MAS) (OR 14.5, P < 0.001), had a greater frequency of adverse reactions to biologic therapy (OR 13.6, P < 0.001), and had higher serum levels of interleukin-18 (IL-18) (median 27,612 pg/ml versus 5,413 pg/ml; P = 0.047). Patients with SJIA-LD lacked genetic, serologic, or functional evidence of granulocyte-macrophage colony-stimulating factor pathway dysfunction, a feature that is typical of familial or autoimmune PAP. Moreover, bronchoalveolar lavage (BAL) fluid from patients with SJIA-LD rarely demonstrated proteinaceous material and had less lipid-laden macrophages than that seen in patients with primary PAP (mean 10.5% in patients with SJIA-LD versus 66.1% in patients with primary PAP; P < 0.001). BAL fluid from patients with SJIA-LD contained elevated levels of IL-18 and the interferon-γ-induced chemokines CXCL9 and CXCL10. Transcriptional profiling of the lung tissue from patients with SJIA-LD identified up-regulated type II interferon and T cell activation networks. This signature was also present in SJIA-LD human lung tissue sections that lacked substantial histopathologic findings, suggesting that this activation signature may precede and drive the lung pathology in SJIA-LD. CONCLUSION Pulmonary disease is increasingly detected in children with systemic JIA, particularly in association with MAS. This entity has distinct clinical and immunologic features and represents an uncharacterized inflammatory LD.
Collapse
Affiliation(s)
- Grant S Schulert
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Shima Yasin
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Brenna Carey
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Claudia Chalk
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Thuy Do
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Andrew H Schapiro
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Ammar Husami
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Allen Watts
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Hermine I Brunner
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Jennifer Huggins
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | | | - Esi M Morgan
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Tracy Ting
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Bruce C Trapnell
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | | | | | - Alexei A Grom
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
| |
Collapse
|
34
|
Gernez Y, de Jesus AA, Alsaleem H, Macaubas C, Roy A, Lovell D, Jagadeesh KA, Alehashemi S, Erdman L, Grimley M, Talarico S, Bacchetta R, Lewis DB, Canna SW, Laxer RM, Mellins ED, Goldbach-Mansky R, Weinacht KG. Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1β inhibition. J Allergy Clin Immunol 2019. [PMID: 31271789 DOI: 10.1016/j.jaci.2019.06.017)] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Affiliation(s)
- Yael Gernez
- Division of Allergy and Immunology, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif.
| | - Adriana A de Jesus
- Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md
| | - Hanouf Alsaleem
- Department of Pediatric Rheumatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada
| | - Claudia Macaubas
- Division of Human Gene Therapy, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - Amitava Roy
- Bioinformatics and Computational Biosciences Branch (BCBB) OCICB Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Mont
| | - Daniel Lovell
- Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | | | - Sara Alehashemi
- Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md
| | - Laura Erdman
- Department of Pediatric Rheumatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada
| | - Michael Grimley
- Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Susanna Talarico
- Department of Pediatric Rheumatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada
| | - Rosa Bacchetta
- Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - David B Lewis
- Division of Allergy and Immunology, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - Scott W Canna
- Division of Rheumatology/RK Mellon Institute, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pa
| | - Ron M Laxer
- Department of Pediatric Rheumatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada
| | - Elizabeth D Mellins
- Division of Human Gene Therapy, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - Raphaela Goldbach-Mansky
- Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md
| | - Katja G Weinacht
- Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif.
| |
Collapse
|
35
|
Khatri S, Hansen J, Mendes AC, Chronakis IS, Hung SC, Mellins ED, Astakhova K. Citrullinated Peptide Epitope Targets Therapeutic Nanoparticles to Human Neutrophils. Bioconjug Chem 2019; 30:2584-2593. [PMID: 31524379 DOI: 10.1021/acs.bioconjchem.9b00518] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Multiple drugs have been proposed for reducing harsh symptoms of human rheumatic diseases. However, a targeted therapy with mild to no side effects is still missing. In this study, we have prepared and tested a series of therapeutic nanoparticles for specific targeting of human neutrophils associated with rheumatoid arthritis. In doing this, a series of citrullinated peptide epitopes derived from human proteins, fibrinogen, vimentin, and histone 3, were screened with regard to specific recognition of neutrophils. The most potent epitope proved to be a mutated fragment of an alpha chain in human fibrinogen. Next, a straightforward synthetic strategy was developed for nanoparticles decorated with this citrullinated peptide epitope and an antisense oligonucleotide targeting disease associated microRNA miR-125b-5p. Our study shows that the nanoparticles specifically recognize neutrophils and knock down miR-125b-5p, with no apparent toxicity to human cells. In contrast to organic dendrimers, chitosan-hyaluronic acid formulations do not activate human innate immune response. Our data proves that the strategy we report herein is effective in developing peptide epitopes for decorating delivery vehicles bearing biological drugs, targeted to a specific cell type.
Collapse
Affiliation(s)
- Sangita Khatri
- Department of Chemistry , Technical University of Denmark , Kongens Lyngby , Region Hovedstaden 2800 , Denmark
| | - Jonas Hansen
- Department of Chemistry , Technical University of Denmark , Kongens Lyngby , Region Hovedstaden 2800 , Denmark.,Institute of Molecular Medicine , Sechenov First Moscow State Medical University , Moscow 119991 , Russia
| | - Ana C Mendes
- DTU Food , Technical University of Denmark , Kongens Lyngby , Region Hovedstaden 2800 , Denmark
| | - Ioannis S Chronakis
- DTU Food , Technical University of Denmark , Kongens Lyngby , Region Hovedstaden 2800 , Denmark
| | - Shu-Chen Hung
- Department of Pediatrics, Program in Immunology , Stanford University School of Medicine , Stanford , California 94305 , United States of America
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology , Stanford University School of Medicine , Stanford , California 94305 , United States of America
| | - Kira Astakhova
- Department of Chemistry , Technical University of Denmark , Kongens Lyngby , Region Hovedstaden 2800 , Denmark
| |
Collapse
|
36
|
Wosen JE, Ilstad-Minnihan A, Co JY, Jiang W, Mukhopadhyay D, Fernandez-Becker NQ, Kuo CJ, Amieva MR, Mellins ED. Human Intestinal Enteroids Model MHC-II in the Gut Epithelium. Front Immunol 2019; 10:1970. [PMID: 31481960 PMCID: PMC6710476 DOI: 10.3389/fimmu.2019.01970] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Accepted: 08/05/2019] [Indexed: 01/14/2023] Open
Abstract
The role of intestinal epithelial cells (IECs) in mucosal tolerance and immunity remains poorly understood. We present a method for inducing MHC class II (MHC-II) in human enteroids, "mini-guts" derived from small intestinal crypt stem cells, and show that the intracellular MHC-II peptide-pathway is intact and functional in IECs. Our approach enables human enteroids to be used for novel in vitro studies into IEC MHC-II regulation and function during health and disease.
Collapse
Affiliation(s)
- Jonathan E. Wosen
- Program in Immunology, Department of Pediatrics, Stanford University, Stanford, CA, United States
| | | | - Julia Y. Co
- Division of Infectious Diseases, Department of Pediatrics, Stanford University, Stanford, CA, United States
| | - Wei Jiang
- Program in Immunology, Department of Pediatrics, Stanford University, Stanford, CA, United States
| | - Dhriti Mukhopadhyay
- Program in Immunology, Department of Pediatrics, Stanford University, Stanford, CA, United States
| | - Nielsen Q. Fernandez-Becker
- Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, CA, United States
| | - Calvin J. Kuo
- Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, United States
| | - Manuel R. Amieva
- Division of Infectious Diseases, Department of Pediatrics, Stanford University, Stanford, CA, United States
- Department of Microbiology and Immunology, Stanford University, Stanford, CA, United States
| | - Elizabeth D. Mellins
- Program in Immunology, Department of Pediatrics, Stanford University, Stanford, CA, United States
| |
Collapse
|
37
|
Gernez Y, de Jesus AA, Alsaleem H, Macaubas C, Roy A, Lovell D, Jagadeesh KA, Alehashemi S, Erdman L, Grimley M, Talarico S, Bacchetta R, Lewis DB, Canna SW, Laxer RM, Mellins ED, Goldbach-Mansky R, Weinacht KG. Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1β inhibition. J Allergy Clin Immunol 2019; 144:1122-1125.e6. [PMID: 31271789 DOI: 10.1016/j.jaci.2019.06.017] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Revised: 06/14/2019] [Accepted: 06/19/2019] [Indexed: 01/04/2023]
Affiliation(s)
- Yael Gernez
- Division of Allergy and Immunology, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif.
| | - Adriana A de Jesus
- Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md
| | - Hanouf Alsaleem
- Department of Pediatric Rheumatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada
| | - Claudia Macaubas
- Division of Human Gene Therapy, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - Amitava Roy
- Bioinformatics and Computational Biosciences Branch (BCBB) OCICB Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Mont
| | - Daniel Lovell
- Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | | | - Sara Alehashemi
- Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md
| | - Laura Erdman
- Department of Pediatric Rheumatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada
| | - Michael Grimley
- Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Susanna Talarico
- Department of Pediatric Rheumatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada
| | - Rosa Bacchetta
- Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - David B Lewis
- Division of Allergy and Immunology, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - Scott W Canna
- Division of Rheumatology/RK Mellon Institute, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pa
| | - Ron M Laxer
- Department of Pediatric Rheumatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada
| | - Elizabeth D Mellins
- Division of Human Gene Therapy, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - Raphaela Goldbach-Mansky
- Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md
| | - Katja G Weinacht
- Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif.
| |
Collapse
|
38
|
Ghosh D, He X, O’Mara ME, Kantor AB, Sengupta D, Yang Y, Eisenlohr LC, Jensen PE, Herzenberg LA, Mellins ED. The class II peptide editor, H2-M, affects the development and function of B-1 cells. The Journal of Immunology 2019. [DOI: 10.4049/jimmunol.202.supp.188.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
B-1 cells are known for their innate, polyreactive BCR repertoire, and proficiency at polarizing T cells towards inflammatory effector T cells, a critical component in host defense and autoimmunity. B-1 cells are antigen presenting cells (APCs) and express MHCII proteins to bind and display self and foreign peptides to CD4 T cells. H2-M edits peptide-MHCII complexes to ensure display of stably bound peptides by APCs. Absence of H2-M has most widely been studied for its impact on T cell activation, but knowledge of how this protein affects the development and function of APCs is lacking. We found that absence of H2-M down-regulated the surface expression and altered the distribution of MHCII molecules in B cells across lymphoid organs. Importantly, in H2-M KO mice, compared to the wild-type C57BL/6 (B6) mice, the frequency and abundance of B-1 cells, but not conventional B-2 cells was affected. Interestingly, the H2-M mediated effect on B-1 cell population was only evident in I-Ab expressing B6, not in Balb/c (I-Ad/I-Ed), indicating an MHCII haplotype dependent effect. Decrease in B-1 cell number was evident in both immature and mature B-1 cells, further indicating an H2-M mediated developmental defect of B-1 cells. In H2-M KO mice, B-1 cells display a significantly lower self-renewal capacity and higher rate of apoptosis compared to WT B6. Despite a lower total B-1 cell number, the frequency of B-1 cells specific for predominant self-antigens (like – phosphatidylcholine) is increased in H2-M KO mice, indicating skewing of B-1 BCR repertoire in absence of H2-M. Collectively, these data identify a novel impact of H2-M/MHCII interaction that regulates the development of B-1 cells and influences the selection of mature B-1 cell clones in the periphery.
Collapse
Affiliation(s)
| | - Xiao He
- 2University of Utah, Department of Pathology
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Yang Z, Yan H, Dai W, Jing J, Yang Y, Mahajan S, Zhou Y, Li W, Macaubas C, Mellins ED, Shih CC, Fitzpatrick JAJ, Faccio R. Tmem178 negatively regulates store-operated calcium entry in myeloid cells via association with STIM1. J Autoimmun 2019; 101:94-108. [PMID: 31018906 DOI: 10.1016/j.jaut.2019.04.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Revised: 04/09/2019] [Accepted: 04/12/2019] [Indexed: 12/27/2022]
Abstract
Store-operated calcium entry (SOCE) modulates cytosolic calcium in multiple cells. Endoplasmic reticulum (ER)-localized STIM1 and plasma membrane (PM)-localized ORAI1 are two main components of SOCE. STIM1:ORAI1 association requires STIM1 oligomerization, its re-distribution to ER-PM junctions, and puncta formation. However, little is known about the negative regulation of these steps to prevent calcium overload. Here, we identified Tmem178 as a negative modulator of STIM1 puncta formation in myeloid cells. Using site-directed mutagenesis, co-immunoprecipitation assays and FRET imaging, we determined that Tmem178:STIM1 association occurs via their transmembrane motifs. Mutants that increase Tmem178:STIM1 association reduce STIM1 puncta formation, SOCE activation, impair inflammatory cytokine production in macrophages and osteoclastogenesis. Mutants that reduce Tmem178:STIM1 association reverse these effects. Furthermore, exposure to plasma from arthritic patients decreases Tmem178 expression, enhances SOCE activation and cytoplasmic calcium. In conclusion, Tmem178 modulates the rate-limiting step of STIM1 puncta formation and therefore controls SOCE in inflammatory conditions.
Collapse
Affiliation(s)
- Zhengfeng Yang
- Department of Orthopaedics, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Hui Yan
- Department of Orthopaedics, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Wentao Dai
- Shanghai Center for Bioinformation Technology & Shanghai Engineering Research Center of Pharmaceutical Translation, Shanghai Industrial Technology Institute, 1278 Keyuan Road, Shanghai, 201203, China
| | - Ji Jing
- Institute of Biosciences and Technology, Texas A&M University College of Medicine, Houston, TX 77030, USA
| | - Yihu Yang
- Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA
| | - Sahil Mahajan
- Department of Orthopaedics, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Yubin Zhou
- Institute of Biosciences and Technology, Texas A&M University College of Medicine, Houston, TX 77030, USA
| | - Weikai Li
- Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA
| | - Claudia Macaubas
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA 94305, USA
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA 94305, USA
| | - Chien-Cheng Shih
- Washington University Center for Cellular Imaging, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - James A J Fitzpatrick
- Washington University Center for Cellular Imaging, Washington University School of Medicine, St. Louis, MO, 63110, USA; Department of Cell Biology & Physiology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neuroscience, Washington University School of Medicine, St. Louis, MO, USA; Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Roberta Faccio
- Department of Orthopaedics, Washington University School of Medicine, St. Louis, MO, 63110, USA; Shriners Hospitals for Children, St. Louis MO, USA.
| |
Collapse
|
40
|
Hung SC, Hou T, Jiang W, Wang N, Qiao SW, Chow IT, Liu X, van der Burg SH, Koelle DM, Kwok WW, Sollid LM, Mellins ED. Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense. J Immunol 2019; 202:2558-2569. [PMID: 30926644 DOI: 10.4049/jimmunol.1801454] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 03/01/2019] [Indexed: 01/28/2023]
Abstract
We have reported that the major histocompatibility molecule HLA-DQ2 (DQA1*05:01/DQB1*02:01) (DQ2) is relatively resistant to HLA-DM (DM), a peptide exchange catalyst for MHC class II. In this study, we analyzed the role of DQ2/DM interaction in the generation of DQ2-restricted gliadin epitopes, relevant to celiac disease, or DQ2-restricted viral epitopes, relevant to host defense. We used paired human APC, differing in DM expression (DMnull versus DMhigh) or differing by expression of wild-type DQ2, versus a DM-susceptible, DQ2 point mutant DQ2α+53G. The APC pairs were compared for their ability to stimulate human CD4+ T cell clones. Despite higher DQ2 levels, DMhigh APC attenuated T cell responses compared with DMnull APC after intracellular generation of four tested gliadin epitopes. DMhigh APC expressing the DQ2α+53G mutant further suppressed these gliadin-mediated responses. The gliadin epitopes were found to have moderate affinity for DQ2, and even lower affinity for the DQ2 mutant, consistent with DM suppression of their presentation. In contrast, DMhigh APC significantly promoted the presentation of DQ2-restricted epitopes derived intracellularly from inactivated HSV type 2, influenza hemagglutinin, and human papillomavirus E7 protein. When extracellular peptide epitopes were used as Ag, the DQ2 surface levels and peptide affinity were the major regulators of T cell responses. The differential effect of DM on stimulation of the two groups of T cell clones implies differences in DQ2 presentation pathways associated with nonpathogen- and pathogen-derived Ags in vivo.
Collapse
Affiliation(s)
- Shu-Chen Hung
- Division of Human Gene Therapy, Department of Pediatrics, Stanford University, Stanford, CA 94305.,Program in Immunology, Stanford University, Stanford, CA 94305
| | - Tieying Hou
- Division of Human Gene Therapy, Department of Pediatrics, Stanford University, Stanford, CA 94305.,Program in Immunology, Stanford University, Stanford, CA 94305
| | - Wei Jiang
- Division of Human Gene Therapy, Department of Pediatrics, Stanford University, Stanford, CA 94305.,Program in Immunology, Stanford University, Stanford, CA 94305
| | - Nan Wang
- Division of Human Gene Therapy, Department of Pediatrics, Stanford University, Stanford, CA 94305.,Program in Immunology, Stanford University, Stanford, CA 94305
| | - Shuo-Wang Qiao
- Centre for Immune Regulation, Department of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.,K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, 0424 Oslo, Norway
| | - I-Ting Chow
- Benaroya Research Institute at Virginia Mason, Seattle, WA 98101
| | - Xiaodan Liu
- Division of Human Gene Therapy, Department of Pediatrics, Stanford University, Stanford, CA 94305.,Program in Immunology, Stanford University, Stanford, CA 94305
| | - Sjoerd H van der Burg
- Department of Medical Oncology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands
| | - David M Koelle
- Department of Medicine, University of Washington, Seattle, WA 98195.,Department of Laboratory Medicine, University of Washington, Seattle, WA 98195; and.,Department of Global Health, University of Washington, Seattle, WA 98195
| | - William W Kwok
- Benaroya Research Institute at Virginia Mason, Seattle, WA 98101
| | - Ludvig M Sollid
- Centre for Immune Regulation, Department of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.,K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, 0424 Oslo, Norway
| | - Elizabeth D Mellins
- Division of Human Gene Therapy, Department of Pediatrics, Stanford University, Stanford, CA 94305; .,Program in Immunology, Stanford University, Stanford, CA 94305
| |
Collapse
|
41
|
Wosen JE, Mukhopadhyay D, Macaubas C, Mellins ED. Epithelial MHC Class II Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts. Front Immunol 2018; 9:2144. [PMID: 30319613 PMCID: PMC6167424 DOI: 10.3389/fimmu.2018.02144] [Citation(s) in RCA: 133] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Accepted: 08/30/2018] [Indexed: 12/13/2022] Open
Abstract
As the primary barrier between an organism and its environment, epithelial cells are well-positioned to regulate tolerance while preserving immunity against pathogens. Class II major histocompatibility complex molecules (MHC class II) are highly expressed on the surface of epithelial cells (ECs) in both the lung and intestine, although the functional consequences of this expression are not fully understood. Here, we summarize current information regarding the interactions that regulate the expression of EC MHC class II in health and disease. We then evaluate the potential role of EC as non-professional antigen presenting cells. Finally, we explore future areas of study and the potential contribution of epithelial surfaces to gut-lung crosstalk.
Collapse
Affiliation(s)
- Jonathan E Wosen
- Program in Immunology, Department of Pediatrics, Stanford University, Stanford, CA, United States
| | - Dhriti Mukhopadhyay
- Program in Immunology, Department of Pediatrics, Stanford University, Stanford, CA, United States
| | - Claudia Macaubas
- Program in Immunology, Department of Pediatrics, Stanford University, Stanford, CA, United States
| | - Elizabeth D Mellins
- Program in Immunology, Department of Pediatrics, Stanford University, Stanford, CA, United States
| |
Collapse
|
42
|
Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM, Thomson W, Kastner DL, Woo P, Ombrello MJ. IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2018; 70:1319-1330. [PMID: 29609200 PMCID: PMC6105455 DOI: 10.1002/art.40498] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Accepted: 03/13/2018] [Indexed: 12/31/2022]
Abstract
OBJECTIVE To determine whether systemic juvenile idiopathic arthritis (JIA) susceptibility loci that were identified by candidate gene studies demonstrate association with systemic JIA in the largest study population assembled to date. METHODS Single-nucleotide polymorphisms (SNPs) from 11 previously reported systemic JIA risk loci were examined for association in 9 populations, including 770 patients with systemic JIA and 6,947 controls. The effect of systemic JIA-associated SNPs on gene expression was evaluated in silico in paired whole genome and RNA sequencing data from the lymphoblastoid cell lines (LCLs) of 373 European subjects from the 1000 Genomes Project. Responses of systemic JIA-associated SNPs to anakinra treatment were evaluated in 38 US patients for whom treatment response data were available. RESULTS We found no association between the previously reported 26 SNPs and systemic JIA. Expanded analysis of the regions containing the 26 SNPs revealed only 1 significant association: the promoter region of IL1RN (P < 1 × 10-4 ). Systemic JIA-associated SNPs correlated with IL1RN expression in LCLs, with an inverse correlation between systemic JIA risk and IL1RN expression. The presence of homozygous IL1RN high expression alleles correlated strongly with a lack of response to anakinra therapy (odds ratio 28.7 [95% confidence interval 3.2-255.8]). CONCLUSION In our study, IL1RN was the only candidate locus associated with systemic JIA. The implicated SNPs are among the strongest known determinants of IL1RN and interleukin-1 receptor antagonist levels, linking low expression with increased systemic JIA risk. Homozygous high expression alleles predicted nonresponsiveness to anakinra therapy, making them ideal candidate biomarkers to guide systemic JIA treatment. This study is an important first step toward the personalized treatment of systemic JIA.
Collapse
Affiliation(s)
- Victoria L. Arthur
- Translational Genetics and Genomics Unit, National Institute of
Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US
Department of Health & Human Services, Bethesda, MD, USA
| | - Emily Shuldiner
- Translational Genetics and Genomics Unit, National Institute of
Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US
Department of Health & Human Services, Bethesda, MD, USA
| | - Elaine F. Remmers
- Inflammatory Disease Section, National Human Genome Research
Institute, National Institutes of Health, US Department of Health & Human
Services, Bethesda, MD, USA
| | - Anne Hinks
- Arthritis Research UK Centre for Genetics and Genomics, Centre for
Musculoskeletal Research, University of Manchester, Manchester, UK
| | - Alexei A. Grom
- Department of Pediatrics, University of Cincinnati, College of
Medicine, Cincinnati, OH, USA
- Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH, USA
| | - Dirk Foell
- Department of Pediatric Rheumatology and Immunology, University
Hospital Münster, Münster, Germany
| | - Alberto Martini
- Direzione Scientifica, G. Gaslini Institute, Genoa, Italy
- Clinica Pediatrica e Reumatologia, G. Gaslini Institute and
University of Genoa, Genoa, Italy
| | - Marco Gattorno
- Clinica Pediatrica e Reumatologia, G. Gaslini Institute and
University of Genoa, Genoa, Italy
| | - Seza Özen
- Department of Pediatric Rheumatology, Hacettepe University, Ankara,
Turkey
| | - Sampath Prahalad
- Departments of Pediatrics and Human Genetics, Emory University
School of Medicine, Atlanta, GA, USA
- Children’s Healthcare of Atlanta, Atlanta, GA
| | - Andrew S. Zeft
- Department of Pediatrics, Cleveland Clinic, Cleveland, OH,
USA
| | - John F. Bohnsack
- Department of Pediatrics, University of Utah, Salt Lake City, UT,
USA
| | - Norman T. Ilowite
- Department of Pediatrics, Albert Einstein College of Medicine and
Children’s Hospital at Montefiore, Bronx, NY, USA
| | | | - Ricardo Russo
- Service of Immunology and Rheumatology, Hospital de Pediatria
Garrahan, Buenos Aires, Argentina
| | - Claudio Len
- Department of Pediatrics, Universidade Federal de São
Paulo, São Paulo, Brazil
| | - Sheila Oliveira
- Universidade Federal de Rio de Janeiro, Rio de Janeiro,
Brazil
| | - Rae S. M. Yeung
- Department of Pediatrics, University of Toronto, Toronto,
Canada
- Department of Immunology, University of Toronto, Toronto,
Canada
- Institute of Medical Science, University of Toronto, Toronto,
Canada
| | - Alan M. Rosenberg
- Department of Pediatrics, University of Saskatchewan, Saskatoon,
Canada
| | - Lucy R. Wedderburn
- University College London Great Ormond Street Hospital Institute of
Child Health, University College London, London, UK
- Center of Paediatric and Adolescent Rheumatology, University
College London, London, UK
- NIHR GOSH Biomedical Research Centre, London, UK
| | - Jordi Anton
- Pediatric Rheumatology Unit, Hospital Sant Joan de Déu,
Universitat de Barcelona, Barcelona, Spain
| | - Johannes-Peter Haas
- German Center for Pediatric and Adolescent Rheumatology,
Garmisch-Partenkirchen, Germany
| | | | - Kirsten Minden
- Charité University Medicine, Berlin, Germany
- German Rheumatism Research Centre, Epidemiology Unit, Berlin,
Germany
| | - Ann Marie Szymanski
- Translational Genetics and Genomics Unit, National Institute of
Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US
Department of Health & Human Services, Bethesda, MD, USA
| | | | - Wendy Thomson
- Arthritis Research UK Centre for Genetics and Genomics, Centre for
Musculoskeletal Research, University of Manchester, Manchester, UK
- National Institute for Health Research Manchester Biomedical
Centre, Central Manchester National Health Service Foundation Trust, Manchester
Academic Health Centre, University of Manchester, Manchester, UK
| | - Daniel L. Kastner
- Inflammatory Disease Section, National Human Genome Research
Institute, National Institutes of Health, US Department of Health & Human
Services, Bethesda, MD, USA
| | - Patricia Woo
- University College London Great Ormond Street Hospital Institute of
Child Health, University College London, London, UK
| | - Michael J. Ombrello
- Translational Genetics and Genomics Unit, National Institute of
Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US
Department of Health & Human Services, Bethesda, MD, USA
| |
Collapse
|
43
|
Zhang Y, Gupta S, Ilstad-Minnihan A, Ayyangar S, Hay AD, Pascual V, Ilowite NT, Macaubas C, Mellins ED. Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor. Clin Immunol 2018; 194:9-18. [PMID: 29928998 DOI: 10.1016/j.clim.2018.06.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Revised: 05/18/2018] [Accepted: 06/16/2018] [Indexed: 01/14/2023]
Abstract
Systemic juvenile idiopathic arthritis (sJIA) is a childhood rheumatic disease of unknown origin. Dysregulated innate immunity is implicated in disease pathology. We investigated if IL-1 inhibition affects circulating cytokines and monocyte gene expression. CD14+ monocytes from patients in the RAPPORT trial were analyzed by RT-PCR for expression of IL1B and transcription factors associated with monocyte activation. Serum IL-1ra decreased with treatment, and IL-18BP transiently increased. Serum levels of IL-1β, IL-6, IL-10 and IL-18 were unchanged. IRF5 and STAT6 were decreased, and PPARG was increased, independent of clinical response, and may represent a skew toward a PPARG-driven M2-like phenotype. IL1B expression was decreased in early clinical responders. A transient increase in STAT1, and a decrease in SOCS1 preceded the reduction in IL1B in early clinical responders. Changes in IL1B/STAT1/SOCS1 could be associated with crosstalk between IL-1 and IFN pathways in sJIA. These transcriptional changes might be useful as drug response biomarkers.
Collapse
Affiliation(s)
- Yujuan Zhang
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USA
| | - Saloni Gupta
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USA
| | | | - Sashi Ayyangar
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USA
| | - Arielle D Hay
- Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA
| | | | - Norman T Ilowite
- Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Claudia Macaubas
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USA.
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USA.
| |
Collapse
|
44
|
Abstract
Juvenile psoriatic arthritis (JPsA), a subtype of juvenile idiopathic arthritis (JIA), constitutes 5% of JIA. The literature is inconsistent regarding features of JPsA, and physicians debate whether it is a distinct entity within JIA. A biphasic age of onset distribution has been noted. Early-onset disease is characterized by female predominance, small joint involvement, dactylitis, and positive antinuclear antibodies. Late-onset JPsA resembles adult-onset psoriatic arthritis (PsA), with male predominance, psoriasis, enthesitis, and axial disease. Recent studies report improved outcomes, likely due to the widespread use of traditional and biologic disease-modifying antirheumatic drugs. Conflicting HLA associations have been reported in JPsA, but notably both HLA class I and II allele associations are suggested. Similar to PsA cohorts, subjects with JPsA have a lower frequency of a protective interleukin 23R allele than controls or other JIA subtypes. Data in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) patient registry suggest the aggressive characteristics of JPsA: 24.6% of children have joint damage 4.6 years after symptom onset. Pediatric and adult PsA classification criteria define different JPsA cohorts within the registry and support a previous suggestion that the International League of Associations for Rheumatology criteria for JPsA may be overly stringent. Increased collaboration between pediatric and adult physicians and comparative research on these clinically related conditions are warranted.
Collapse
Affiliation(s)
- Devy Zisman
- From the Department of Rheumatology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University, Stanford, California, USA.
- D. Zisman, MD, Senior Lecturer, Department of Rheumatology, Carmel Medical Center, and Director of Rheumatology Unit, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; M.L. Stoll, MD, PhD, MSCS, Associate Professor, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; Y. Butbul Aviel, MD, Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; E.D. Mellins, MD, Professor, Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University.
| | - Matthew L Stoll
- From the Department of Rheumatology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University, Stanford, California, USA
- D. Zisman, MD, Senior Lecturer, Department of Rheumatology, Carmel Medical Center, and Director of Rheumatology Unit, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; M.L. Stoll, MD, PhD, MSCS, Associate Professor, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; Y. Butbul Aviel, MD, Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; E.D. Mellins, MD, Professor, Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University
| | - Yonatan Butbul Aviel
- From the Department of Rheumatology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University, Stanford, California, USA
- D. Zisman, MD, Senior Lecturer, Department of Rheumatology, Carmel Medical Center, and Director of Rheumatology Unit, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; M.L. Stoll, MD, PhD, MSCS, Associate Professor, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; Y. Butbul Aviel, MD, Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; E.D. Mellins, MD, Professor, Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University
| | - Elizabeth D Mellins
- From the Department of Rheumatology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University, Stanford, California, USA
- D. Zisman, MD, Senior Lecturer, Department of Rheumatology, Carmel Medical Center, and Director of Rheumatology Unit, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; M.L. Stoll, MD, PhD, MSCS, Associate Professor, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; Y. Butbul Aviel, MD, Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; E.D. Mellins, MD, Professor, Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University
| |
Collapse
|
45
|
Macaubas C, Gaertner F, Yeh CL, Rajasekaran N, Ilstad-Minnihan A, Nakamura MC, Mellins ED. A myeloid population potentially corresponding to myeloid monocytic suppressor cells (MoMDSCs) is increased in the blood of Rheumatoid Arthritis patients and associated with osteoclastogenesis. The Journal of Immunology 2018. [DOI: 10.4049/jimmunol.200.supp.45.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
The development of erosive arthritis and joint damage are common and severe complications of rheumatoid arthritis (RA). Erosions are caused by excessive activity of osteoclasts (OCs), the only known bone resorbing cells. OCs are myeloid lineage cells and can be generated in vitro from CD14+ circulating myeloid cells, using RANKL and M-CSF. To characterize circulating myeloid lineage cells in RA, we performed mass cytometry (CyTOF) analysis of blood from 11 RA patients and 10 age and gender-matched healthy controls. Using CITRUS analysis, we found a myeloid cell cluster that is significantly elevated in RA patients compared to healthy subjects. The phenotype of this cluster is CD11b+, CD14+, CD16−, HLA-DR-/lo, CCR2hi, RANKhi, and phosphorylated (p)STAT3hi. The surface phenotype of this cluster is associated with monocytic myeloid derived suppressor cells (MoMDSCs). Analysis by conventional flow of a separate group of 14 RA patients showed that frequency of these myeloid cells correlates with number of blood osteoclasts precursors (OCP) based on the in vitro assay. Baseline level of pSrc and pJNK in these cells also correlated with OCP numbers. Both of these molecules are involved in downstream signaling cascades involved in osteoclastogenesis and osteoclast survival. We also found that intermediate (CD14++CD16+) monocytes are elevated in RA, as previously described, but these cells did not show a positive correlation with OCP numbers. These results indicate that a group of myeloid cells, potentially corresponding to MoMDSCs, are elevated in the blood of RA patients. Their phenotype (high RANK, phosphorylated Src, phosphorylated JNK) and frequency indicate that they may be involved in osteoclastogenesis, as described in mouse models.
Collapse
|
46
|
Hung SC, Rajasekaran N, Zhu S, Ma Z, Ghosn E, Mellins ED. Single-walled carbon nanotubes target neutrophils and Ly-6Chi monocytes and localize to joints in murine models of arthritis. The Journal of Immunology 2018. [DOI: 10.4049/jimmunol.200.supp.175.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease that often leads to joint damage. The etiology of RA remains unclear, but new insights and therapeutic strategies have been facilitated by murine models. In the K/BxN serum transfer (STA) model, arthritis is triggered by autoantibodies against glucose-6-phosphate isomerase. The SKG model has a ZAP70 point mutation that reduces TCR signaling. After zymosan exposure, SKG mice develop arthritis, mediated by autoreactive Th17 cells. Joint inflammation in these models shares many features with RA, including leukocyte invasion, synovitis, and bone resorption. Neutrophils and Ly-6Chi monocytes are known to play critical roles in these models.1–4 Here, we investigated single-walled carbon nanotubes (SWNT) as candidate drug carriers to specifically target pathogenic cells in arthritic joints. Using FACS analysis, we found that, 2h and 4h after IV administration of SWNT, nearly 80% Ly-6Chi monocytes in blood had taken up SWNT in STA and SKG model, respectively. Near-infrared (NIR) photoluminescence whole-animal imaging of the STA model showed that SWNT were first detected in arthritic joints 3h post injection (p.i.) and reached a maximal level 24h p.i., In contrast, in non-arthritic mice, SWNT detected in joints remained low 24h p.i., suggesting SWNT can specifically target cells homing to or present in arthritic joints. In SKG mice, 2d p.i., SWNT were found in Ly-6Chi monocyte and in neutrophils in bone marrow and liver, but not in blood and spleen. FACS analysis indicated specific uptake of SWNT labelled with Cy5.5 in monocytes and neutrophils in human blood. We conclude that SWNT is a potential carrier to target drugs to pathogenic neutrophils and monocytes in arthritic joints.
Collapse
|
47
|
Hinks A, Marion MC, Cobb J, Comeau ME, Sudman M, Ainsworth HC, Bowes J, Becker ML, Bohnsack JF, Haas JP, Lovell DJ, Mellins ED, Nelson JL, Nordal E, Punaro M, Reed AM, Rose CD, Rosenberg AM, Rygg M, Smith SL, Stevens AM, Videm V, Wallace CA, Wedderburn LR, Yarwood A, Yeung RSM, Langefeld CD, Thompson SD, Thomson W, Prahalad S. Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70:957-962. [PMID: 29426059 PMCID: PMC5984672 DOI: 10.1002/art.40443] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 02/01/2018] [Indexed: 02/03/2023]
Abstract
Objective Juvenile idiopathic arthritis (JIA) comprises 7 heterogeneous categories of chronic childhood arthritides. Approximately 5% of children with JIA have rheumatoid factor (RF)–positive arthritis, which phenotypically resembles adult rheumatoid arthritis (RA). Our objective was to compare and contrast the genetics of RF‐positive polyarticular JIA with those of RA and selected other JIA categories, to more fully understand the pathophysiologic relationships of inflammatory arthropathies. Methods Patients with RF‐positive polyarticular JIA (n = 340) and controls (n = 14,412) were genotyped using the Immunochip array. Single‐nucleotide polymorphisms were tested for association using a logistic regression model adjusting for admixture proportions. We calculated weighted genetic risk scores (wGRS) of reported RA and JIA risk loci, and we compared the ability of these wGRS to predict RF‐positive polyarticular JIA. Results As expected, the HLA region was strongly associated with RF‐positive polyarticular JIA (P = 5.51 × 10−31). Nineteen of 44 RA risk loci and 6 of 27 oligoarticular/RF‐negative polyarticular JIA risk loci were associated with RF‐positive polyarticular JIA (P < 0.05). The RA wGRS predicted RF‐positive polyarticular JIA (area under the curve [AUC] 0.71) better than did the oligoarticular/RF‐negative polyarticular JIA wGRS (AUC 0.59). The genetic profile of patients with RF‐positive polyarticular JIA was more similar to that of RA patients with age at onset 16–29 years than to that of RA patients with age at onset ≥70 years. Conclusion RF‐positive polyarticular JIA is genetically more similar to adult RA than to the most common JIA categories and thus appears to be a childhood‐onset presentation of autoantibody‐positive RA. These findings suggest common disease mechanisms, which could lead to novel therapeutic targets and shared treatment strategies.
Collapse
Affiliation(s)
- Anne Hinks
- University of Manchester, Manchester, UK
| | - Miranda C Marion
- Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Joanna Cobb
- University of Manchester and Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - Mary E Comeau
- Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Marc Sudman
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Hannah C Ainsworth
- Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - John Bowes
- University of Manchester, Manchester, UK
| | | | | | | | - Johannes-Peter Haas
- German Centre for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany
| | - Daniel J Lovell
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | | | - J Lee Nelson
- Fred Hutchinson Cancer Research Center and University of Washington, Seattle
| | - Ellen Nordal
- University Hospital of North Norway and UIT The Arctic University of Norway, Tromsø, Norway
| | - Marilynn Punaro
- Arthritis Clinic Texas Scottish Rite Hospital for Children and University of Texas Southwestern Medical Center, Dallas
| | - Ann M Reed
- Duke University School of Medicine, Durham, North Carolina
| | | | | | - Marite Rygg
- Norwegian University of Science and Technology and St. Olav's University Hospital, Trondheim, Norway
| | | | - Anne M Stevens
- Seattle Children's Research Institute and University of Washington, Seattle
| | - Vibeke Videm
- Norwegian University of Science and Technology and St. Olav's University Hospital, Trondheim, Norway
| | - Carol A Wallace
- Seattle Children's Hospital and Research Institute, Seattle, Washington
| | - Lucy R Wedderburn
- University College London and NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK
| | | | - Rae S M Yeung
- The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada
| | - Carl D Langefeld
- Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | | | - Wendy Thomson
- University of Manchester and Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - Sampath Prahalad
- Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia
| |
Collapse
|
48
|
Samuelsen S, Jørgensen CD, Mellins ED, Torok KS, Astakhova K. Detection of autoimmune antibodies in localized scleroderma by synthetic oligonucleotide antigens. PLoS One 2018; 13:e0195381. [PMID: 29641558 PMCID: PMC5895021 DOI: 10.1371/journal.pone.0195381] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Accepted: 03/21/2018] [Indexed: 01/08/2023] Open
Abstract
In this study, we developed a series of synthetic oligonucleotides that allowed us to investigate the details on the antigen recognition by autoimmune antibodies in localized scleroderma subjects. Besides dramatically improved analytical specificity of the assay, our data suggests a potential linking for antibodies to DNA to the biological status of disease state in localized scleroderma. Moreover, introducing chemical modifications into short synthetic deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules completely changed the binding titers of corresponding antibodies and their clinical relevance. The strongest observed effect was registered for the localized scleroderma skin damage index (LoSDI) on the IgG antibodies to TC dinucleotide-rich double-stranded antigen (p < 0.001). In addition to providing valuable tools for diagnosis of clinically relevant biomarkers, we believe that this work opens up new opportunities for research on antibodies to nucleic acids in localized scleroderma and other autoimmune diseases.
Collapse
Affiliation(s)
- Simone Samuelsen
- Department of Chemistry, Technical University of Denmark, Kongens Lyngby, Region Hovedstaden, Denmark
| | | | - Elizabeth D. Mellins
- Department of Pediatrics, Program in Immunology, Stanford University School of Medicine, Stanford, California, United States of America
| | - Kathryn S. Torok
- Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Kira Astakhova
- Department of Chemistry, Technical University of Denmark, Kongens Lyngby, Region Hovedstaden, Denmark
- * E-mail:
| |
Collapse
|
49
|
Klecka M, Thybo C, Macaubas C, Solov'yov I, Simard J, Balboni IM, Fox E, Voss A, Mellins ED, Astakhova K. Autoantibody Profiling in Lupus Patients using Synthetic Nucleic Acids. Sci Rep 2018; 8:5554. [PMID: 29615791 PMCID: PMC5883037 DOI: 10.1038/s41598-018-23910-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Accepted: 03/19/2018] [Indexed: 02/08/2023] Open
Abstract
Autoantibodies to nuclear components of cells (antinuclear antibodies, ANA), including DNA (a-DNA), are widely used in the diagnosis and subtyping of certain autoimmune diseases, including systemic lupus erythematosus (SLE). Despite clinical use over decades, precise, reproducible measurement of a-DNA titers remains difficult, likely due to the substantial sequence and length heterogeneity of DNA purified from natural sources. We designed and tested a panel of synthetic nucleic acid molecules composed of native deoxyribonucleotide units to measure a-DNA. ELISA assays using these antigens show specificity and reproducibility. Applying the ELISA tests to serological studies of pediatric and adult SLE, we identified novel clinical correlations. We also observed preferential recognition of a specific synthetic antigen by antibodies in SLE sera. We determined the probable basis for this finding using computational analyses, providing valuable structural information for future development of DNA antigens. Synthetic nucleic acid molecules offer the opportunity to standardize assays and to dissect antibody-antigen interactions.
Collapse
Affiliation(s)
- Martin Klecka
- Department of Chemistry, Technical University of Denmark, Kemitorvet 206, 2800, Kgs, Lyngby, Denmark
| | - Christina Thybo
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark
| | - Claudia Macaubas
- Department of Pediatrics, Program in Immunology, Stanford University School of Medicine, 269 Campus Drive, Stanford, California, 94305, USA
| | - Ilia Solov'yov
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark
| | - Julia Simard
- Department of Health and Research Policy, Stanford University School of Medicine, 150 Governor's Lane, Stanford, California, 94305, USA
| | - Imelda Maria Balboni
- Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology, Stanford University, 700 Welch Rd. Suite 301, Stanford, California, 94304, USA
| | - Emily Fox
- Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology, Stanford University, 700 Welch Rd. Suite 301, Stanford, California, 94304, USA
| | - Anne Voss
- Department of Rheumatology, Odense University Hospital, J. B. Winsløws Vej 19, 2, 5000, Odense C, Denmark
| | - Elizabeth D Mellins
- Department of Pediatrics, Program in Immunology, Stanford University School of Medicine, 269 Campus Drive, Stanford, California, 94305, USA.
| | - Kira Astakhova
- Department of Chemistry, Technical University of Denmark, Kemitorvet 206, 2800, Kgs, Lyngby, Denmark.
| |
Collapse
|
50
|
Samad A, Stoll ML, Lavi I, Hsu JJ, Strand V, Robinson TN, Mellins ED, Zisman D. Adiposity in Juvenile Psoriatic Arthritis. J Rheumatol 2017; 45:411-418. [PMID: 29247150 DOI: 10.3899/jrheum.170598] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/26/2017] [Indexed: 01/20/2023]
Abstract
OBJECTIVE Adult patients with psoriatic arthritis are at increased risk for obesity and metabolic syndrome, but data regarding adiposity in children with juvenile psoriatic arthritis (JPsA) are limited. Our study assessed adiposity in children with JPsA in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry. METHODS Patients with JPsA in the CARRA registry were divided into nonoverweight and overweight groups using recommendations from the US Centers for Disease Control, and differences in demographic and clinical characteristics between groups at baseline and after 1-year followup were assessed using chi-square test, Fisher's exact test, T test, or Mann-Whitney U test, as appropriate. The prevalence of overweight status in the JPsA registry patients was compared to rheumatoid factor-positive and -negative polyarticular juvenile idiopathic arthritis (RF+polyJIA; RF-polyJIA) registry cohorts and the US pediatric population, using a chi-square goodness-of-fit test. RESULTS Overweight children represented 36.3% of this JPsA cohort (n = 320). Compared to nonoverweight children, they were significantly older at symptom onset and rheumatologist's first assessment, and scored significantly worse on patient/physician outcome measures. At 1-year followup, changes in body mass index were not associated with changes in clinical features or outcome measures. The prevalence of overweight and obesity in patients with JPsA was significantly higher than in RF+polyJIA patients, RF-polyJIA patients, and the US pediatric population. CONCLUSION In this registry, almost 1 in 5 patients with JPsA were obese and more than one-third were overweight. This is significantly more than expected compared to the US pediatric population, and appropriate longterm followup of this JPsA subgroup is warranted.
Collapse
Affiliation(s)
- Aaida Samad
- From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.,A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion
| | - Matthew L Stoll
- From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.,A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion
| | - Idit Lavi
- From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.,A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion
| | - Joyce J Hsu
- From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.,A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion
| | - Vibeke Strand
- From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.,A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion
| | - Thomas N Robinson
- From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.,A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion
| | - Elizabeth D Mellins
- From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.,A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion
| | | | | |
Collapse
|